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Allison L Kuipers, PhD 
University of Pittsburgh, 2011
 
Cardiovascular disease (CVD) is a major public health concern, especially in African ancestry 
populations, which have greater risk compared with Caucasians. Subclinical CVD measures 
provide information on the health of the vasculature and are predictive of future risk of clinical 
events. Vascular health indices have been associated with lower bone mineral density (BMD) 
and osteoporosis suggesting a potential common etiology. Intima-media thickness (IMT) and 
arterial diameter (adventitial diameter [AD] and lumen diameter [LD]) are subclinical CVD 
measures obtained by carotid ultrasound, whereas pulse pressure (PP) and pulse-wave velocity 
(PWV) are subclinical measures of arterial stiffness. The genetic influence on these subclinical 
CVD measures and in the link between CVD and osteoporosis has not been well defined in 
African ancestry populations. Therefore, we have estimated genetic heritability, genetic 
correlation of CVD and osteoporosis related traits, and performed univariate and bivariate 
genome-wide linkage analysis of these traits in 7 large, multigenerational families of African 
ancestry from the Caribbean island of Tobago. A total of 461 individuals aged ≥18 years were 
included in these analyses from probands and families who were recruited without regard to their 
health status. After removing the effects of covariates, subclinical CVD traits were all heritable 
and there was significant phenotypic and genetic correlation between CVD and osteoporosis 
related traits. The most promising evidence of linkage was detected for AD-BMD trait-pairs on 
chromosome 14 (max LOD=5.2) in bivariate analysis and for AD and LD on chromosome 11 
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(max LOD=4.1) in univariate analysis. The linkage regions contain several genes known to be 
involved in cardiovascular disease including the ApoA1/C3/A4/A5 gene cluster, IL18, BMP4, and 
ESR2. Further studies of these regions may reveal novel insight into the genetic regulation of 
subclinical CVD and osteoporosis. These findings have public health significance because 
determining the genetic regulation of chronic disease may aid in risk prediction and, ultimately, 
minimize health disparities in African ancestry populations. 
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1.0  SPECIFIC AIMS 
Cardiovascular disease (CVD) is the leading cause of death in the US. Major risk factors for 
CVD include hypertension, diabetes and dyslipidemia. Diet, obesity, exercise, tobacco use and 
alcohol consumption are among the most common, modifiable environmental factors affecting 
CVD risk; however, genetic factors are also well-recognized determinants of CVD. African 
ancestry individuals have greater risk of CVD compared to Caucasians. Yet, African ancestry 
individuals also have a more favorable lipid profile and in some studies less coronary 
atherosclerosis than Caucasians. African ancestry populations tend to have much higher blood 
pressure and prevalence of diabetes than Caucasians, although the increase in CVD risk appears 
to be independent of these factors. 
Subclinical CVD can be assessed using multiple methods. Atherosclerosis and vascular 
adaptation can be assessed via carotid ultrasound scans yielding measures of carotid artery 
intima-media thickness (IMT), adventitial diameter (AD) and lumen diameter (LD). Pulse-wave 
velocity (PWV) is a non-invasive measure of arterial stiffening, or arteriosclerosis, which can be 
measured using automated tonometry devices. Pulse pressure (PP) is also a marker of arterial 
stiffness and reflects the difference between systolic and diastolic blood pressures. Each of these 
measures is correlated with traditional risk factors for CVD and is predictive of future CVD 
events and mortality, but the extent to which genetics influence these traits in African ancestry 
individuals is not well known. Most studies of subclinical CVD genetics have been primarily in 
Caucasian populations, or in persons of admixed African descent, such as African Americans. 
However, given the difference in risk factor profiles and subsequent risk of disease in African 
ancestry populations, studies specifically characterizing the genetics of subclinical 
atherosclerosis in homogeneous African ancestry populations are warranted.  
An association of osteoporosis related indices and cardiovascular disease has been well 
documented. For instance, bone mineral density has been inversely associated with subclinical 
and clinical CVD, albeit in Caucasian populations, even after adjusting for potential confounding 
factors, such as age, body size, dyslipidemia, diabetes and hypertension. The underlying 
physiologic link between these two disease processes is not completely understood; perhaps, 
these processes are connected through calcium or other bone metabolism pathways. For the most 
part, these observations have been epidemiologic or experimental. The potential for pleiotropic 
genetic effects on bone and the cardiovascular system has not been investigated. Also, there has 
been little investigation of this link in populations of African ancestry. Studies in African 
ancestry individuals could provide additional and unique insight on the CVD-osteoporosis 
relationship since African ancestry populations tend to have stronger bones but more adverse 
CVD than their Caucasian counterparts. The proposed dissertation research addressed the 
following specific aims: 
 
AIM 1: To estimate the residual heritability of and perform genome-wide linkage analysis 
on common carotid artery traits (IMT, AD and LD). We quantified the genetic influence on these 
traits and identified genomic regions that may control their variance in 395 men and women 
from seven, large, Afro-Caribbean families from the island of Tobago. 
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AIM 2: To estimate the residual heritability of and perform genome-wide linkage analysis 
on PWV, brachial PP and blood pressure indices. We quantified the extent of genetic influence 
on these traits and identified genomic regions that may control their variance in 361 men and 
women from seven, large, Afro-Caribbean families from the island of Tobago. 
 
AIM 3: To estimate the shared environmental and genetic effects between measures of 
subclinical CVD (IMT, AD and LD) and bone mineral density, bone geometry and bone strength 
in 461 men and women from seven, large, Afro-Caribbean families from the island of Tobago. 
Where appropriate, bivariate, genome-wide linkage analyses were used to identify genomic 
regions that may jointly influence the CVD and bone related traits. 
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2.0  INTRODUCTION  
2.1 CARDIOVASCULAR DISEASE 
Cardiovascular disease (CVD) is the leading cause of death in Westernized countries. In the 
United States in 2006, CVD affected 36.9% of the population1 and 26.0% of deaths were 
attributed to diseases of the heart, while cerebrovascular disease was the underlying cause of 
5.7% of all deaths2. For comparison, all types of malignancies were the cause of death in 23% of 
all deaths2. Currently, it is estimated that more than 1 of every 3 Americans has some type of 
prevalent CVD, including high blood pressure, coronary heart disease (CHD), heart failure (HF) 
or stroke1. There are marked differences in the prevalence of CVD by ethnicity. Heart disease is 
more prevalent in Whites than in Blacks (12.1% vs. 10.2%, respectively), however, hypertension 
(HT) and history of stroke are more prevalent in Blacks than in Whites (HT: 31.8% vs. 23.3%; 
stroke: 3.6% vs. 2.7%, respectively)1. Asian ethnicities have a lower prevalence of heart disease, 
HT and stroke than any other ethnic group1. While men have a greater CVD burden than women 
of all ages, this relationship appears to be ethnicity dependent. For example, CVD prevalence is 
higher in White men than in White women (38.1% vs. 34.4%, respectively) whereas CVD 
prevalence is greater in Black women than in Black men (46.9% vs. 44.6%, respectively)1. These 
differences in CVD are independent of potential confounders and are observed in different areas 
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of the world3, suggesting there may be significant biologic differences in the pathophysiology of 
CVD between men and women and between different ethnicities. 
Tobago is a Caribbean island off of the coast of Venezuela and is a part of the island 
nation of Trinidad and Tobago. The population of Tobago, with 51,000 inhabitants (1990 
census4), has <3% admixture and is mostly of West African origin5, 6. Trinidad and Tobago has 
only in the last 50 years gone through the Epidemiologic Transition; wherein, the majority of 
public health burden comes from complex diseases such as CVD and cancers rather than 
infectious diseases and infant mortality5. Thus, the people of Tobago represent an African 
ancestry population with high risk for CVD that is newly representative of the Westernized 
world in lifestyle factors, but which is not greatly influenced by admixture. 
2.1.1 Atherosclerosis 
Atherosclerosis is characterized by the formation of plaques throughout the large arteries of the 
vasculature and is thought to occur via acute inflammatory responses to endothelial injury in the 
lining of the lumen7. These plaques primarily form in the intimal layer of the arterial wall and are 
composed of a lipid-rich core and a fibrous cap8.  Initially, as a plaque grows, the artery attempts 
to keep the blood pressure and blood flow shear stress constant against the endothelium of the 
lumen; therefore, the vessel expands outward, increasing the adventitial diameter, but keeping 
the lumen diameter constant8-11. However, as atherosclerosis progresses and the plaques increase 
in size, blood flow through the lumen can become partially occuluded8-11. This is not the usual 
cause of death from atherosclerosis. Fatalities can occur when the plaque is generally unstable 
and is predisposed to rupture, at which time an acute inflammatory response is elicited from the 
contents of the plaque, including oxidized lipids, smooth muscle cells and other fibrous cellular 
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components, flowing into the blood stream. This results in the formation of a thrombosis, which 
can travel to the heart or brain leading to myocardial infarction or stroke, respectively. 
There have been many risk factors associated with atherosclerosis ranging from lifestyle 
habits to biochemical measures, some of which are modifiable, while others are not. The three 
strongest risk factors for atherosclerosis are unmodifiable: age, sex and ethnicity12-14. The risk of 
atherosclerosis more than doubles from the age of 65 to the age of 8515. Most studies of 
cardiovascular risk have been conducted in White populations and show that the risk of 
atherosclerosis is greatest in men12-15; however, the relationship is reversed in Black populations 
where women have greater atherosclerotic risk16-18. Additionally, traditional risk factors for 
atherosclerosis are high total- or low-density lipoprotein (LDL)- cholesterol, low high-density 
lipoprotein (HDL)-cholesterol, high systolic blood pressure (SBP), cigarette smoking and 
diabetes12.  
A tool for risk prediction of coronary events, such as myocardial infarction (MI) or death 
due to coronary heart disease (CHD), was developed based on these risk factors and is able to 
identify persons at high 10-year risk for a coronary event - the Framingham Risk Score (FRS)12. 
However, the FRS is not able to completely identify each individual who will develop 
atherosclerosis. The observation of a meaningful number of events occurring in individuals with 
only intermediate 10-year risk has lead to years of research into potential risk factors that can 
further stratify those who would benefit from aggressive early intervention versus those for 
whom additional intervention is not necessary. Additional risk factors not assessed in the FRS, 
but that are associated with CVD include obesity19, C-reactive protein (CRP)7, 13, coronary artery 
calcium (CAC)13, 17, carotid intima-media thickness (cIMT)13, 17, ankle-brachial index (ABI)13, 17, 
lipoprotein(a)13, 17, homocysteine13, leukocyte count13, fasting glucose13, periodontal disease13, 
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metabolic syndrome17, treadmill exercise response17 and family history17. However, the clinical 
utility of the FRS in non-White populations is uncertain. 
2.1.2 Arteriosclerosis 
Arteriosclerosis is the progressive stiffening of arteries that occurs with age. Arterial stiffness 
generally disrupts the hemodynamics of the vasculature and is predictive of mortality, heart 
failure, myocardial infarction, stroke, coronary heart disease, dementia and target organ 
damage20-24. Increased vascular stiffness leads to faster pressure waves, which increases central 
pulse pressure (PP) via increased SBP and leads to isolated systolic hypertension20. If the arteries 
are very stiff, waves reflected at branching points of the vascular tree can return to the heart 
during systole instead of diastole, thereby increasing central PP, which can be quantified by the 
augmentation index (AIx)20-22. The early return of the pressure wave causes left ventricular 
hypertrophy leading to poor cardiac profusion and decreased cardiac output, and eventually heart 
failure22, 24. The endothelium of stiff arteries is characterized by a decrease of properly formed 
elastin molecules, an increase in collagen, disarrayed endothelial cells, fibrosis and infiltration by 
smooth muscle cells and inflammatory proteins21, 24, 25. The central elastic arteries incur the 
greatest degree of stiffening, while more peripheral arteries tend to be spared, although, they are 
stiffer than central arteries in healthy individuals and at young ages20, 24. While arteries stiffen 
with age, additional factors such as hypertension, salt intake26, glucose regulation27, 
neuroendocrine signaling28 and matrix metalloproteinases are also contributing factors of arterial 
stiffening20, 24. Additionally, arterial stiffness tends to be greater in populations of African 
ancestry than in whites, even after adjusting for blood pressure and additional CVD risk factors29, 
30. 
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 While direct characterization of arterial stiffness is possible via catheterization, the most 
common and appropriate way to assess arterial stiffness, non-invasively, is via PWV21, 31, which 
will be described in more detail in Section 2.2.3. Additionally, waveform analysis, which 
measures AIx, is another indicator of arterial stiffness that can be obtained non-invasively using 
applanation tonometry21, 32. Elevated central PP and isolated systolic hypertension are also 
indicative of central arterial stiffening; however, neither they nor AIx are the preferred markers 
of arteriosclerosis because they are dependent on the speed of the wave21. Therefore, non-
invasive measures of PWV are the most informative for assessing arterial stiffness in clinical 
practice and epidemiologic studies. 
2.2 SUBCLINICAL CARDIOVASCULAR DISEASE 
2.2.1 Carotid Intima-Media Thickness 
Intima-media thickness is the distance from the lumen-intima interface to the media-adventitial 
interface and is, thus, the thickness of the intimal and medial layers of a vessel wall. In beginning 
stages of the CVD process, there is thickening of the vascular intima as oxidized lipids and 
inflammatory cells infiltrate the endothelial layer from the lumen11. Additionally, the gradual 
stiffening of the vasculature with age also results in thicker vessels from build up of collagen and 
fibrous material24. The most common location of IMT measurement for assessment of 
subclinical CVD is at the carotid artery. This location is easily viewable using non-invasive, 
ultrasound techniques33-35.  
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Briefly, current B-mode ultrasonography techniques endorsed by the American Society 
of Echocardiography33 include having the participant lie in a supine position, slightly 
hyperextend their neck and tilt their head approximately 45° away from the scanning probe. 
Then the sonographer starts with a transverse and longitudinal scan of the complete accessible 
carotid artery to assess the degree and presence of plaques within the vessel. The cIMT imaging 
proceeds with longitudinal assessment of the carotid segment to be measured. The images are 
captured during diastole then analyzed at a subsequent time. These methods allow visualization 
of the common carotid IMT, internal carotid IMT and the bifurcation IMT and are usually 
conducted on both the left and ride side of the neck33-35.  
It is possible to clearly visualize both the near and far walls of the common carotid artery, 
which provides a less variable cIMT measure because of the ability to use a mean measure, and 
is less dependent on the exact position of the ultrasound transducer33. However, there tends to be 
less plaque in this segment of the vessel and thus may not provide a complete description of 
underlying disease. Plaques form more readily in the carotid bulb and ICA. Unfortunately, these 
segments are much more difficult to visualize and only the far wall of the vessel can be 
accurately measured33, 35. This technological limitation increases the variation of any one 
measurement in these segments and means the measure is highly dependent on the placement of 
ultrasonographic transducer. Some studies choose to only assess common cIMT as it is highly 
reproducible and has lower variability34, while others assess all carotid segments in order to have 
a broader description of the vessel thickness. 
Each type of cIMT measurement appears to have a similar correlation with the amount of 
atherosclerosis within the entire body36, 37. Since ultrasound techniques cannot determine the 
intima from the media, it is not possible to determine if increased IMT is directly reflective of the 
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atherosclerotic process within the intima and not due to arteriosclerosis.  However, there is a 
large body of evidence attesting to the observation that cIMT is associated with the level of 
atherosclerosis in the coronary arteries, the lower extremities and to arterial calcification37. 
Kablak-Ziembicka et. al. conducted a comprehensive study of the correlation and potential 
predictive value of cIMT with multi-level stenoses identified through invasive means36. They 
studied 415 patients with suspected coronary disease admitted to their clinic over a 6-month 
period. The participants underwent cIMT imaging for a mean aggregate measure of cIMT in the 
three carotid segments and ultrasonographic assessment of stenosis (defined as a focal plaque 
occluding >50% of the lumen) in the supra-aortic and iliac/femoral arteries, and angiography of 
the coronary and renal arteries. Patients were grouped according to number of arterial beds with 
significant lesions, which was then correlated with the cIMT measure. This study not only found 
that cIMT was highly correlated with number of arterial beds with significant stenosis (r=0.751, 
P<0.001), but in a multivariate model, cIMT was the single greatest predictor of the level of 
atherosclerosis.  
Carotid IMT is also associated with traditional cardiovascular risk factors and predictive 
of future CVD events and mortality. Large, prospective studies of cIMT progression have been 
conducted in multiple cohorts including the Atherosclerosis Risk in Communities study38, 39, the 
Carotid Atherosclerosis Progression Study40, the Cardiovascular Health Study41, the Malmö Diet 
and Cancer Study42 and the Rotterdam Study43. Each study showed that increased cIMT 
measure, which differed between studies, was associated with a greater risk of myocardial 
infarction (MI), stroke or death, depending on outcome assessed. A meta analysis of these data in 
2007 provided an overall hazard ratio of 1.26 (95% CI:1.21-1.30) and 1.32 (95% CI: 1.27-1.38) 
for the risk of MI and stroke, respectively, for every 1 standard deviation increase in common 
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carotid artery IMT after adjustment for age and sex44. These significant hazard ratios persisted 
after additional adjustment for traditional CVD risk factors, which were also significant 
covariates of IMT in these studies, such as BMI, systolic and diastolic BP, cholesterols, smoking 
and diabetes (MI HR[95% CI]: 1.17[1.13-1.22]; stroke HR[95% CI]: 1.23[1.18-1.28])44. In 
addition to these risk factors, IMT has also been shown to correlate with lipoprotein(a), oxidized 
LDL, homocysteine, C-reactive protein and metabolic syndrome, in some studies45.  
 The difference in IMT between Black and White ethnicities has only been studied in 
smaller populations (n<1000). However, Blacks have consistently been shown to have thicker 
cIMT than Whites on average46, 47. There is evidence that this difference is only independent of 
other CVD risk factors at the common carotid artery segment, but not at the bifurcation and/or 
internal carotid artery, where most of prevalent plaques form46, 47. This is consistent with the 
general observation that Blacks have less heart disease than Whites for a given risk factor 
profile1, and perhaps, the thickening at the common carotid artery is more reflective of vascular 
adaptation to hypertension than atherosclerosis. 
2.2.2 Adventitial and Lumen Diameters 
Arterial diameters are assessed during the carotid ultrasound scan with two measures: adventitial 
diameter (AD) and lumen diameter (LD). Adventitial diameter is the distance from the near-wall 
media-adventitia interface to the far-wall media-adventitia interface. Lumen diameter is the 
distance from the near-wall lumen-intima interface to the far-wall lumen-intima interface. 
Initially, as a plaque deposition occurs and hemodynamics of blood flow change with aging, the 
artery attempts to keep the blood pressure and blood shear stress constant against the 
endothelium of the lumen; therefore, the vessel expands outward, increasing the diameter, while 
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keeping the lumen a constant size8-11, 23. However, as atherosclerosis progresses and the plaques 
increase in size, the LD eventually narrows and the lumen becomes obstructed8-11, 23. Unlike 
cIMT, AD and LD can only be accurately assessed using the ultrasonography methods described 
above at the common carotid artery where the near-wall is more easily visible33. However, while 
some studies do report on the internal carotid artery AD, this measure should be interpreted 
cautiously33.  
Eigenbrodt et. al. showed that in healthy participants, arteries widen with age suggesting 
that arterial remodeling is a natural part of the aging process48. However, they also found the 
association to be much stronger in persons with prevalent CVD, suggesting that in the presence 
of cardiovascular risk factors and/or disease, this process occurs to a greater degree and, thus, 
arterial diameter is also reflective of adverse vascular health48. These observations are in 
accordance with a smaller study by Terry et. al.49. However, that study may have been invalid 
because they reported major findings from the internal carotid artery, which is known to be prone 
to measurement error49. Additionally, it has been shown that the AD is associated with prevalent 
MI and future cardiac events50, although only a small portion of the information from AD is 
significantly associated with these events outside of the IMT measurement in older adults51. 
The carotid artery tends to be larger in men than in women, which may be explained 
through the positive association of vessel diameter with height. Vessels need to be larger in taller 
individuals to allow sufficient blood volume to flow through the vessels without increasing 
pressure10, 11, 23. Therefore, age, sex and height are variables that should be included in analyses 
of arterial diameter in order to assess the independence of any association from these main 
determinants. In addition to these factors, arterial diameter is also associated with CVD risk 
factors, such as obesity, systolic blood pressure, glucose, cholesterol, triglycerides, heart rate, 
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apolipoproteins, prevalent atherosclerotic plaques and Framingham Risk Score52, 53. Common 
carotid lumen diameter is greater in Blacks than in Whites, suggesting that there are less plaques, 
even after adjustment for confounding factors53. This also supports the observation that there is 
less heart disease in Blacks compared to Whites1 with similar risk profiles. 
2.2.3 Pulse-Wave Velocity 
Direct methods of assessing arterial stiffness involve angiography to insert a catheter into the 
arterial segment of interest to simultaneously measure pressure and arterial diameter change31. 
However, these methods are very invasive and not generally applicable to large epidemiologic 
studies. Pulse-wave velocity is the most widely used and the most appropriate, accurate and 
valid, non-invasive measurement of arterial stiffness in epidemiologic studies21. This measure 
consists of monitoring the pulse-wave at different arterial beds throughout the body including the 
aorta, carotid, brachial, femoral and ankle arteries, and calculating how long it takes for the wave 
to travel from one location to the next. The gold standard for measurement of central stiffness is 
the carotid-femoral PWV (cfPWV)21, 54. This is because it is most reflective of central stiffening 
without influence from peripheral vessels and resembles the actual propagation of blood through 
the vasculature21. However, the measurement of the femoral artery pulse-wave can be physically 
difficult to obtain in persons with diabetes, metabolic syndrome or obesity55. Also, presence of 
central stenosis can alter the flow of the pulse-wave and result in erroneous time 
measurements55. A novel device from the Colin corporation measures PWV at the brachial and 
ankle (tibial) arteries and simultaneously measures blood pressure through the use of pressure 
cuffs on the arm and ankle56. Because this device does not obtain PWV measurements at the 
femoral artery, it is more appropriate for use in a wider variety of populations.  
13 
One technical consideration of the brachial-ankle PWV (baPWV) is that because it 
measures the pulse wave at the ankle, it is not only reflective of central stiffness57, but of 
peripheral stiffness, as well, which is not usually of clinical interest21. However, a study by 
Sugawara et. al. indicates that the determination of baPWV by central stiffness (R=0.55) is 
similar to other PWV measures, suggesting the influence of peripheral artery stiffness doesn’t 
diminish the utility of this measure58. Another study reported that in individuals with a moderate 
amount of stenosis in the peripheral arteries, as defined by an ABI<0.95, the baPWV measure 
may not be accurate because of the influence of the occluded vessels on the pulse-wave59.  
Overall, there is generally good reproducibility from the baPWV measures with inter-observer 
and intra-observer correlations of 0.98 and 0.87, respectively and corresponding coefficients of 
variations of 8.4% and 10.0%, respectively56. These are similar to reproducibility with other 
measures of PWV and are better than other measures of arterial stiffness such as AIx (coefficient 
of variation 13.0%)54. 
Brachial-ankle and other measures of PWV are associated with and predictive of future 
cardiovascular events and disease. Carotid-femoral PWV, which has been the most widely 
studied measure of PWV, has been shown to be predictive of cardiovascular mortality in 
hypertensives60, end-stage renal disease patients61, 62, persons with impaired glucose tolerance63, 
the elderly64-66 and in the general population67, 68. It is also predictive of future coronary heart 
disease events, such as MI, revascularization and angina pectoralis in hypertensives69 and the 
elderly64, 65, as well as with fatal strokes in hypertensives70. Brachial-ankle PWV has been 
associated with coronary artery disease56, 71, presence of abdominal aortic calcification72 and 
adds significantly to discriminating risk of future CVD as assessed by the FRS73. However, it is 
critical to note that the majority of studies using the baPWV measurement have been conducted 
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in Japanese populations where the Colin device was developed. Replication of these findings in 
other ethnic groups is crucial to determining the utility of baPWV in CVD-related risk 
prediction.   
 In addition to clinical CVD events, PWV has also been associated with CVD risk factors 
such as age, sex, hypertension, obesity, the metabolic syndrome, diabetes, dyslipidemia, 
smoking, homocysteine, C-reactive protein and race, in cross-sectional studies21. Pulse-wave 
velocity appears to be higher for men than women at younger ages74, but after the menopausal 
transition, PWV in women greatly increases creating a quadratic curve in the relationship 
between PWV and age73-75. Pulse wave velocity also appears to be correlated with severity of 
hypertension, such that higher blood pressures are associated with higher PWV, especially in 
older individuals, as would be expected76. Obesity and the metabolic syndrome are conditions 
that have been repeatedly associated with increased PWV. It appears that central adiposity, 
particularly visceral fat, may have the strongest association with PWV77 and this association as 
well as the association with the metabolic syndrome may be more evident in women than men78-
80. Additionally, baPWV may be more informative than cfPWV as a measure of diabetic 
complication severity because it includes some information of the health of the peripheral, small 
artery, vasculature81. Measures of arterial stiffness tend to be worse in Blacks than in Whites, 
even after adjustment for hypertension and/or blood pressure80, 82. This suggests that there may 
be an underlying physiologic difference between races that cannot be explained by traditional 
CVD risk factor profiles alone. 
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2.2.4 Pulse Pressure 
Pulse pressure (PP) is the difference of systolic blood pressure (SBP) and diastolic blood 
pressure (DBP). As arteries stiffen, SBP increases but DBP is unaffected, therefore, the gap 
between the two measures widens. Thus, PP is a measure of the gap between SBP and DBP. 
Naturally, PP increases due to the gradual arterial stiffness associated with age83-85. It was 
recognized in early epidemiologic studies that blood pressure measures, including PP, are 
predictive of future mortality and cardiovascular events86-89. The first measures of PP were taken 
at the brachial artery where SBP and DBP are traditionally measured. However, it has been more 
recently noted that brachial PP may not be the same as central PP90 and, therefore, may not be as 
reflective of central arterial stiffness and predictive of cardiovascular outcomes. 
Brachial PP is greater than central PP because of amplification of the pulse-wave in the 
peripheral arteries91, 92. As the pulse-wave travels away from the aorta, the systolic pressure 
increases due to the smaller, more muscular arteries with a greater number of branch points. This 
effect is seen more in younger individuals (<50 years), who can be ‘diagnosed’ with isolated 
systolic hypertension from brachial blood pressure measures because of the artifact of amplified 
pulse pressures93. This increase in PP is not due to increased resistance in stiff arteries, but, 
conversely, due to the normal hemodynamics of healthy arteries in the periphery93. The major 
factor associated with this amplification outside of physiologic features is heart rate85, 94. As the 
heart rate increases, the amplification in peripheral arteries is smaller and, therefore, peripheral 
artery blood pressure measures are more closely related to central measures. This explains that, 
with age, the brachial and central measures are more similar; also, men have less of an impact of 
the pressure amplification than women, because they have greater heart rate85. 
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However, there are other noninvasive measures of PP that reflect central PP 95, 96that are 
more applicable to clinical settings than the invasive, catheterization techniques of direct central 
PP acquisition97. The first is to use applanation tonometry at the carotid artery to determine SBP 
and DBP and calculate PP from that, since the carotid artery is elastic, like the aorta and central 
arteries, so it is not susceptible to pressure amplification. The second technique is to use 
applanation tonometry at the brachial or radial (peripheral) arteries and then use a standardized 
transfer function to equate that measure to the relative central PP21, 95, 96, 98, 99. While there has 
been debate to the generalizability of the transfer functions, they are generally accepted as an 
appropriate approximation for central PP98, 99. However, they do not exactly replicate the central 
values100. 
The important distinction, however, is whether this inherent inaccuracy in brachial PP 
measures is clinically relevant. In studies that tried to assess this issue, central PP was found to 
be a better predictor of future cardiovascular events101, 102 and is a better marker of underlying 
disease103, 104 than brachial PP. However, that is not to say that brachial PP does not have clinical 
use. Brachial PP has been associated with future mortality89, CHD mortality87, CHD events86, 105, 
MI88, left ventricular hypertrophy101, decreased ejection fraction101 and IMT103, 104. Although, in 
a small study of 180 end-stage renal disease patients, only central PP was associated all-cause 
and cardiovascular mortality102. Overall, most studies with large sample size conclude that, while 
central PP may be the best measure of cardiovascular risk, brachial PP is still a viable assessment 
tool when central PP is unavailable. 
 As expected, brachial PP is associated with traditional CVD risk factors. Pulse pressure 
increases with increasing age and tends to be greater in men than women83-85, 106, 107. By 
definition, it is also associated with essential hypertension107. In addition, it has shown to be 
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associated with BMI106, diabetes106, 107, hypercholesterolemia106-108, smoking107, 109 and prevalent 
CVD107. Along with age and sex, heart rate is the other, most important risk factor for increased 
PP107. Also, brachial PP was greater in African ancestry individuals compared to Whites in two 
very large multi-center studies106, 110. One of the studies in over 26,000 participants from 
America, found an interaction of ethnicity and age, sex, BMI and diabetes, such that, in African 
ancestry individuals, the effect of these CVD risk factors is multiplicatively worse than the effect 
seen in White individuals106. This suggests there may be an underlying physiologic difference in 
pressure regulation between ethnicities that is related to the differential rates of hypertension1. 
2.3 SUBCLINICAL CARDIOVASCULAR DISEASE GENETICS 
2.3.1 Carotid Intima-Media Thickness Genetics 
Heritability (h2), or genetic heritability, is a measure of the potential genetic contributions to the 
variance in a trait. Residual heritability (h2r) is a measure of the potential genetic contributions to 
the variance in a trait after the effects of environmental covariates are removed. Heritability in 
the broad sense is defined as the proportion of the total trait variance due to the genetic variance 
and is given by the following: h2broad = σ2G / σ2T where h2 is the heritability estimate, σ2G is the 
genetic variance and σ2T is the total trait variance111. The genetic variance can further be divided 
into additive and dominance effects, where additive genetic effects are those that are due to the 
number copies of an allele (0, 1 or 2) at any of the modeled polygenic loci. Dominance effects 
account for any shift from a strictly additive model; all single gene effects have an additive 
component but only those that deviate from the additive model have a dominance component. 
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Heritability is calculated using only additive genetic effects is called narrow sense heritability 
and is given by the following: h2narrow = σ2A / σ2T where h2 is the heritability estimate, σ2A is the 
additive genetic variance and σ2T is the total trait variance111. In both of these equations, it is 
important to note that because heritability is a proportion of the total trait variance, as that 
variance changes the estimate of heritability would also change111. Thus, heritability estimates 
are always population-specific. All methods for estimating heritability in large family studies can 
only estimate narrow sense heritability because they only model additive genetic variance112.  
Heritability of cIMT has been estimated in 17 studies113-129 (Table 2.6.1). The reported 
estimates of residual heritability range from 0.16126 to 0.92129 with only one study reporting non-
significant heritability118. Regardless of the population studied, covariates included for 
adjustment or the exact measure of common carotid artery IMT (ccaIMT) used, the majority of 
studies reported heritability estimates between 0.30 and 0.50. In studies that also reported 
estimates for other arterial segments127, 128, ccaIMT had the highest h2r with ICA and the 
bifurcation having lower heritability and a larger influence of environmental covariates. 
Therefore, there is consistent evidence that cIMT is at least partially heritable and warrants 
further genetic studies to identify potentially important genomic regulators of these traits.  
The study that estimated a h2r of 0.92129 was the first heritability estimate published for 
cIMT in 1996 and has not yet been replicated. This high heritability estimate may have been 
inflated due to a low sample size, admixture and/or improper statistical methods. The study that 
found no significant evidence of heritability 118 was also based on a fairly small sample size of 
twin-pairs. Only two studies included African Americans114, 125, and only one reported ethnic 
specific heritability114. Although based on a small sample size, the h2r estimate for ccaIMT 
among 175 African Americans was 0.72 compared to 0.38 among 973 European Americans and 
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0.41 in the full sample. Therefore, it appears that cIMT is also heritable within different ethnic 
groups. 
Since cIMT is heritable, many studies have been attempted to identify specific allelic 
variants contributing to inter-individual differences in these traits. Five genome-wide association 
or linkage studies have been performed for these traits114, 120, 130-132, along with over 300133 
candidate gene association studies. The first genome-wide linkage analysis of cIMT was 
conducted in the Framingham Heart Study Offspring Cohort, a White sample recruited from the 
general population of Framingham, Massachusetts132. This study did not detect even suggestive 
evidence for linkage for ccaIMT; however, there was a significant linkage signal for the internal 
carotid artery IMT (icaIMT) on chromosome 12 at 161 cM.  
A genome-wide association study using 100,000 single nucleotide polymorphisms (SNP) 
was also conducted in the Framingham Offspring Cohort130. Generalized estimating equations 
(GEE) and family-based association tests (FBAT) were used to control for the relatedness of 
individuals and perform linkage analyses. Also, this study analyzed many subclinical 
atherosclerosis traits including ccaIMT, icaIMT, ABI, stenosis and arterial calcification. The five 
most significant results for GEE and FBAT for ccaIMT were located on chromosomes 5 (no 
gene), 17 (MYOID), 18 (2 hits, no gene) and 20 (PCSK2). There were no significant or 
suggestive signals of linkage for ccaIMT. The five most significant results for GEE and FBAT 
for icaIMT were located on chromosomes 3 (no gene), 4 (no gene), 5 (EFNA5), 12 (no gene) and 
17 (near KRTAPI-1 and KRTAPI-3). There was also significant evidence for linkage on 
chromosomes 1 (max LOD = 4.23) and 12 (max LOD = 5.05). 
The Diabetes Health Study114 conducted linkage analysis of families affected with type 2 
diabetes (T2D) in Forsythe County, NC including both European American (EA) and African 
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American (AA) participants. This study identified suggestive evidence of linkage on 
chromosomes 1 (EA only, 52 cM, LOD = 2.18), 13 (EA with T2D, 61 cM, LOD 2.27) and 21 
(EA with T2D, 25 cM, LOD = 2.33). There were no linkage signals in the AA sample; however, 
there were only 72 African Americans included in that study. 
The Northern Manhattan Study120 conducted linkage analysis of cIMT traits in Caribbean 
Hispanics recruited from probands at high risk for cardiovascular events. This study examined 
ccaIMT, icaIMT, bifurcation IMT and an aggregate IMT measure. There was no evidence of 
linkage for ccaIMT or icaIMT. However, significant evidence for linkage with mean bifurcation 
IMT was found on chromosome 7 (7p14.3, 51 cM, LOD = 3.10) and suggestive evidence of 
linkage with mean aggregate IMT was found on chromosome 14 (14q31.1, 95 cM, LOD = 2.30). 
Genetic association between SNPs from a targeted cardiovascular candidate gene array 
and aggregate mean cIMT was examined in the Study of Health Assessment and Risk in Ethnic 
Groups cohort 131. This study included individuals of South Asian, Chinese and European 
Caucasian ancestry in Ontario. The array included ~50,000 SNPs that were chosen to encompass 
~2100 cardiovascular candidate genes. The most consistent association with cIMT was for 
rs3791395 in HDAC4 (chromosome 2). Additional genes with significant associations were 
NPR1 (chromosome 1), COL1A2 (chromosome 7), SH3GL2 (chromosome 9), CARKL 
(chromosome 17) and XRCC1 (chromosome 19). 
 There have also been 384 published candidate gene association reports as summarized in 
a meta-analysis published in 2010133. The most widely studied genes, as defined by being 
analyzed in >1 study and in a total of >5000 participants, were APOE (apolipoprotein E, 
chromosome 19), ACE (angiotensin I converting enzyme, chromosome 17), MTHFR (5, 10-
methylenetetrahydrofolate reductase, chromosome 1), NOS3 (nitric oxide synthase 3, 
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chromosome 7) and ADD1 (adducin 1, chromosome 4). Only APOE demonstrated consistent 
association with cIMT in all subsets in meta-analyses. APOE has also been the most extensively 
studied candidate gene in Black populations.   
2.3.2 Adventitial and Lumen Diameter Genetics 
There has been little work published on the genetics of arterial diameter. The only study to 
estimate the heritability of arterial size was by North et. al.122 in the Strong Heart Family Study 
among extended Native American families. The residual heritability of lumen diameter was 0.44, 
which was greater than the estimate for ccaIMT of 0.21. This observation suggests that carotid 
arterial diameters may be under greater genetic control than cIMT. However, neither this study 
nor any other, to our knowledge, has reported residual heritability estimates for AD.  
 Likewise, most genetic association studies have only analyzed minimum LD, since it is a 
surrogate for plaque severity. Polymorphisms in several candidate genes have been associated 
with LD, including apolipoprotein A-V (APOA5), microsomal triglyceride transfer protein large 
(MTTP)134, and interleukin-6 (IL-6)135. Additionally, no association was detected between 
minimal LD and a candidate locus on chromosome 9p21136, 137 or with the ACE gene138. Given 
the greater heritability of LD than IMT, there is a considerable need for additional research 
investigating the genetic determinants of carotid arterial diameters. 
2.3.3 Pulse-Wave Velocity Genetics 
The heritability of PWV has been reported in 7 studies113, 119, 139-143 (Table 2.6.2). Significant 
residual heritabilities ranged from 0.19141 to 0.54142 and two studies reported no significant 
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heritability for carotid-brachial PWV (cbPWV)139, 140. Carotid-femoral PWV is the most often 
analyzed trait, however, other measures were reported. There have been no heritability estimates 
for baPWV reported. The only study that included Blacks did not assess heritability in stratified 
subgroups defined by ethnicity142. The overall estimates of aortic-radial and aortic-foot PWVs 
were adjusted for ethnicity (h2r: 0.43 and 0.54, respectively), which doesn’t take into account the 
population specific nature of heritability. Each study represents a different, and sometimes very 
discrete, population with different measures of PWV and covariate modeling.  
In general, heritability estimates were similar between the different measures of PWV, 
except in studies that included carotid-brachial PWV139, 140. In both cases, cfPWV was reported 
to be significantly heritable (0.40). However, cbPWV had a heritability estimate <0.10 with large 
standard errors (>0.10); thus, cbPWV does not appear to be heritable in the populations assessed 
to date. These data raise the possibility that central aortic stiffness as assessed by cfPWV may be 
more genetically determined than PWV measures that represent a mix of both elastic, central and 
muscular, peripheral arteries. However, the sample in the study by Ge et. al. used aortic-radial 
and aortic-foot PWV measures, both of which are reflective of the periphery, and reported 
significant residual heritabilities for both measures142.  
There have also been three genome-wide studies of PWV variables139, 140, 144. A linkage 
analysis of cfPWV and cbPWV in the Framingham Offspring Study139 identified four regions 
suggestive of linkage, but no significant signals. The suggestive peaks were on chromosomes 2 
(94 cM, LOD = 2.46), 7 (29 cM, LOD = 2.5), 13 (108 cM, LOD = 2.10) and 15 (108 cM, LOD = 
2.48). 
A genome-wide association study based on 100,000 SNPs in the family-based 
Framingham Heart Study140 reported significant genetic associations for cfPWV and cbPWV 
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using GEE and FBAT, even though the cbPWV was not heritable in their population. Significant 
genetic association with cfPWV was identified on chromosomes 12 (USP15, GEE only) and 4 
(ARHGAP24, FBAT only). They also identified one genomic region with evidence for 
significant linkage on chromosome 2 (LOD = 3.04), as well as, three regions suggestive of 
linkage on chromosomes 4 (LOD = 2.17), 15 (LOD = 2.43) and 18 (LOD = 2.68). They did not 
identify any genomic region in even suggestive linkage with cbPWV. 
A genome-wide association study of 500,000 SNPs and PWV in a family-based sample 
of 4221 individuals from the Mediterranean island of Sardinia144 was also completed. The top 85 
associations were tested for replication using an independent cohort of 1828 Sardinians and an 
additional sample of 831 Old-Order Amish. Consistent associations with two SNPs were 
observed in the Sardinians with one SNP in COL4A1 (collagen type IV alpha 1, chromosome 13) 
and another in MAGI1 (membrane associated guanylate kinase, chromosome 3). However, only 
the COL4A1 SNP association was replicated in the Old-Order Amish.  
 Candidate gene association studies for arterial stiffness have focused on four major 
categories of genes, including the renin-angiotensin-aldosterone (RAA) pathway genes, matrix 
metalloproteinase (MMP) genes, endothelial cell-related (ECR) genes and inflammatory 
response genes145, 146. Gene products from the RAA and MMP categories, as well as, nitric-oxide 
(NO) ECR genes are directly involved in vessel wall elasticity and response. Variants in genes 
from the RAA pathways that have been associated with PWV including SNPs in the angiotensin 
II type 1 receptor (AGTR1)147, the angiotensin converting enzyme (ACE)148 and aldosterone 
synthase (CYP11B2)149. A genome-wide association study replicated an association between 
SNPs in the CYP11B2 gene and arterial stiffness150, providing stronger evidence for the 
involvement of this gene in arterial stiffness. SNPs in the MMP3 and MMP9 genes have been 
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associated with arterial stiffness indices, but only variation in MMP9 has been associated with 
PWV151. The most widely studied NO gene is NOS3 encoding endothelial nitric oxide synthase. 
Like CYP11B2, SNPs in NOS3 have been widely replicated in candidate gene152 and genome-
wide139 studies, affirming that NOS3 is a strong candidate gene for arterial stiffness. Additional 
genes that may be involved in PWV variation identified from association studies include 
estrogen-related genes153, part of the ECR group, and inflammatory genes such as interleukin-6 
(IL6)154 and others155. Additionally, the 9p21 locus, which has been associated with clinical 
cardiovascular disease156, 157, has also been associated with PWV. However, there are no known 
genes in this region; thus, the mechanisms underlying the 9p21 association remain unclear. 
2.3.4 Pulse Pressure Genetics 
Pulse pressure heritability has been estimated in 19 studies113, 139, 141, 150, 158-172 (Table 2.6.3). All 
but one139 of these studies used traditional brachial PP instead of central PP measures. In all but 
one report141, PP has been heritable with estimates ranging from 0.11160-0.54170, suggesting there 
is good evidence that PP has some genetic component. The high estimate of heritability comes 
from a study of twin-pairs, which are known to give higher estimates of heritability due to the 
shared environmental factors. However, the greatest heritability estimate within a family study 
was still moderate at 0.49 in a group of Mexican American Families158. Yet, heritability 
estimates tended to be relatively low, between 0.2 and 0.4, in the majority of family studies. The 
one study reporting central PP had an estimated heritability of 0.35139 and was in accordance 
with other brachial PP measures.  
There are conflicting results of the magnitude of heritability for PP compared to other 
blood pressure traits. In some samples that report PP, SBP and DBP, PP has the greater 
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heritability than blood pressure traits160, 164, 166, 168, 171, but in an equal amount of other studies, 
SBP has the greatest heritability158, 159, 162, 170, 172. Similar to other blood pressure traits, PP seems 
to be under low to moderate genetic control in most populations. There have been more studies 
that quantified the genetic effect of PP in populations of African descent165-167, 170, 172 compared 
to other CVD traits for which few heritability studies have been conducted in non-White 
populations. This is likely due to the significantly greater prevalence of hypertension and blood 
pressure dysregulation in Blacks than in Whites1. These studies reported similar heritability as 
studies in the other, mainly White, populations (range h2r: 0.13172-0.54170; max h2r in families: 
0.43166). 
There have also been eight genome-wide studies of PP139, 150, 160, 161, 164, 167, 169, 171. These 
were all linkage studies in related individuals and only one studied used central PP measures139. 
There have been consistent findings for genomic regions suggestive of linkage with PP on 
chromosome 21150, 167 (all 2.0<LOD<3.0). However, these are not very strong signals for linkage 
and the potentially causal genes have not been refined or discussed, as there are many genes 
under this peaks and none have been previously associated with PP. There has been significant 
linkage (LOD>3.0) identified on chromosomes 7 (max LOD = 3.30, 37 cM)161, 11 (max LOD = 
3.02, 17 cM)164 and 18 (max LOD = 3.20, 75 cM)167. The region on chromosome 7 contains two 
previously studied cardiovascular-related genes: interleukin-6 (IL6) and neuropeptide Y (NPY). 
This linkage peak was identified in the Strong Heart Family Study in American Indian 
families161 and may represent an ethnic group specific signal since it has never been replicated. 
Two regions further downstream on chromosome 7 have suggestive evidence of linkage in the 
Framingham Offspring cohort139, 169, but do not overlap with each other or with the peak 
identified in the Strong Heart study. 
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The significant peak on chromosome 11 was identified in non-Hispanic White siblings 
from the GENOA study who were diagnosed with hypertension before the age of 60164. While 
this univariate linkage peak is also unique to this population, this study also reported significant 
bivariate linkage with PP and brain atrophy also in this region. This suggests that the region on 
chromosome 11 may play a greater role in determining PP in the brain and/or be related to early 
onset of essential hypertension since that is the sample studied. Nonetheless, there are genes 
under this peak that have been previously studied in a general cardiovascular context: insulin 
(INS), calcitonin gene-related peptide (CALCA/CALCB) and adrenomedullin (ADM).  
The significant linkage peak identified on chromosome 18 was initially identified in a 
very large study in Black, Asian, Hispanic and White families (total n = 10,798)167. The 
significant signal was identified in the overall population, but not in any of the race-specific 
analyses, perhaps due to sample size constraints. Interestingly, a meta-analysis of linkage studies 
for PP that used these data as part of their report, found that the peak persisted through meta-
analysis (rank p = 0.027)173. This was also the only peak in the meta-analysis containing a 
previously studied, candidate gene for PP: neural precursor cell expressed, developmentally 
down-regulated 4-like (NEDD4L). In addition, other CVD-related genes included: solute carrier 
family 14 members 1 and 2 (SLC14A1/SLC14A2), serpin peptidase inhibitor, clade B, member 2 
(SERPINB2), mex3 homolog C (RKHD2) and melanocortin 4 receptor (MC4R). In addition to 
the peak on chromosome 18, the meta-analysis identified suggestive linkage peaks on 
chromosome 8 and 21 in the full cohort (rank p = 0.044 and 0.028, respectively), as well as, 
chromosome 22 and 10 in European Americans only (rank p = <0.001 and 0.031, respectively). 
Each of these peaks had been previously identified in one of the studies included in the meta-
analysis except the peak on chromosome 10. 
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The report using central PP was conducted in the Framingham Offspring cohort139. They 
did not identify any genomic regions with significant linkage to central PP. The largest peak was 
on chromosome 15 (max LOD = 2.92, 122 cM), followed by chromosome 7 (max LOD = 2.85, 
172 cM) and chromosome 9 (max LOD = 2.72, 160 cM). The region on chromosome 15 was 
also identified in a semi-overlapping cohort, the Framingham Heart Study, and contains many 
potentially causal genes including insulin-like growth factor 1 receptor (IGF1RI), myocyte 
enhancer factor 2A (MEF2A), chondroitin sulfate synthase 1 (CHSY1) and proprotein convertase 
subtilisin/kexin type 6 (PACE4). However, the other two regions are unique to this study and 
could suggest differential genetic determinants of central and brachial PP. 
 There have been over 80 published reports of candidate gene studies for general PP 
focusing on genes related to vessel wall structure, sympathetic nervous system, lipid metabolism, 
inflammation, NO metabolism and the rennin-angiotensin system. Genes related to the vessel 
structure with significant association with PP include fibrillin1 (FBN1: 15q21.1)174 and 
plasminogen activator inhibitor (SERPINE1: 7q21.3-22)175. The sympathetic nervous system 
regulates hemodynamics and the beta2-adrenergic receptor, within that pathway, has also been 
associated with PP (ADRB2: 5q31-32). Lipoprotein genes with significant associations to PP 
include apolipoprotein B (APOB: 2p24-23)176, apolipoprotein C-III (APOC3: 11q23.1-23.2) and 
lipoprotein lipase (LPL: 8p22)177. While the inflammation pathway is assumed to be important to 
all cardiovascular-related traits, the only gene associated with PP is TNF receptor superfamily, 
member 6 (FAS: 10q24.1)155. Both the NO and RAS pathways have been widely studied in 
relation to CVD genetics, including PP. Notably, the nitric oxide synthase 3 gene, which has 
been associated with many CVD traits, is associated with PP (NOS3: 7q36)152. The RAS pathway 
genes have been most consistently associated with PP including angiotensin II type 1 receptor 
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(AT1R: 3q24)178 angiotensin II type 2 receptor (AT2R: 8p22)179, angiotensin (AGT: 1q42-43)178, 
180 and angiotensin converting enzyme (ACE: 17q23.3)64. 
2.4 OSTEOPOROSIS AND CARDIOVASCULAR DISEASE 
2.4.1 Epidemiology 
Both CVD and osteoporosis (OP) risk and prevalence increase with age181. More recently, 
however, epidemiologic studies have demonstrated that this correlation is independent of age and 
other traditional risk factors182. Studies have focused on investigating the correlation of arterial 
calcification and calcified plaque with bone mineral density (BMD) and fractures in various 
populations including individuals with CKD and post-menopausal women, in addition to, general 
population samples of Whites, Mexican Americans and Japanese183-188. However, this 
relationship has not been adequately investigated in populations of African ancestry, even though 
there is a low risk of OP and high risk of CVD events compared with Caucasians. Additionally, 
correlation between arterial calcification and osteoprotegerin (OPG), a protein involved in bone 
metabolism, has been reported in epidemiologic studies186. There have also been reports on 
measures of CVD risk other than arterial calcification, such as PAD, arterial stiffness, intimal-
medial thickening, dyslipidemia, diabetes and the metabolic syndrome, and their correlation with 
bone loss186, 189-203. Therefore, the relationship between CVD and OP appears to be more than 
just the association of both diseases with vascular calcification.  
Arterial stiffness, as assessed by PWV, has been shown to be inversely associated with 
BMD in post-menopausal women186, 192, 194, 195. Three of these studies assessed the relationship in 
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Asian women from Japan192, 195 or Korea194, while the fourth was in Caucasian European women 
in London186. Each study was very small with sample sizes of less than 350 women. In each 
study, multivariate models included BMD at the lumbar spine, femur or total hip as a predictor of 
PWV (baPWV in the first three and cfPWV for the fourth) independent of other CVD risk 
factors, such as age, body size and blood pressure. Additionally, this correlation has also been 
reported in patients with chronic kidney disease in the US204, Australia205 and Japan188.  
However, vascular calcification is also very severe in these patients so this correlation may be 
confounded by the effect of calcification in stiffening vessels and its interference in accurate 
BMD assessment205. The extent to which the relationship between PWV and BMD exists in the 
general population and in African ethnicities is unknown. 
Subclinical atherosclerosis, as assessed by IMT, has also been associated with low 
BMD191, 193, 198, 206. Two of the studies examined the correlation of cIMT and BMD in Mexican 
Americans, first in just women198, then in men and women in a slightly different cohort193. In the 
471 Mexican American women, cIMT was directly correlated with spine BMD, but not radius or 
hip BMD, after adjustment for age and BMI198.  However, in the larger study of Mexican 
American men and women (n=870)193, cIMT was directly correlated with hip BMD in younger 
women (<60 years), but inversely correlated with hip, spine and radius BMD in older women 
(>60 years).  Similarly, in younger men there was a direct correlation between IMT and distal 
radius BMD, but an inverse correlation between cIMT and distal and mid radius BMDs.  These 
findings suggest there may be sex and age affects on the relationship between IMT and BMD. 
Other smaller studies in post-menopausal Japanese (n=325)191 and Moroccan (n=72)206 women 
have also found correlations between cIMT and lumbar spine and proximal femur BMDs 
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independent of age and body size. Again, there have been no studies in individuals of African 
ancestry. 
 Additionally, atherosclerosis in the periphery, assessed by ABI, has also been reported to 
be directly correlated with BMD189, 190, 197, 199. Three of these studies were large (n>1000), 
population-based studies conducted in the Caucasian men and women in the US (n=1,778)190, 
Caucasian and African American older men in the US (n=5,781)199, and Chinese older men and 
women from Hong Kong (n=3,957)189. The fourth study was in 368 Italian post-menopausal 
women197. The study that investigated the association in older men, which was the largest study, 
found that men with PAD (ABI<0.9) had the greatest BMD loss at total hip, trochanter and 
femoral neck (p=0.02, 0.02, 0.001, respectively) after adjustment for many risk factors for CVD 
and osteoporosis. The next largest study of individuals in Hong Kong, only found a weak, 
positive correlation between ABI and total hip BMD (r=0.05, P<0.05) after adjustment for risk 
factors. Likewise, in the other study in the US, there was only a borderline association of PAD 
with greater bone loss at the total hip (P=0.05) in women only190. However, even in the smaller 
sample of post-menopausal, Italian women, femoral neck BMD was one of the strongest 
predictors of PAD after adjustment for additional risk factors. Given the conflicting results on 
the strength of this association in the general population, further research needs to be done. The 
largest study included African American individuals, but ethnicity was only adjusted for; thus, 
the association of PAD and BMD has not yet been addressed in a homogeneous African ancestry 
population.   
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2.4.2 Potential Mechanisms Linking Bone Metabolism with CVD 
Each of the discussed measures of subclinical CVD have also been shown to be positively 
associated with serum OPG186, 196, 207-210 and other markers of bone metabolism and turnover208, 
211, suggesting that there may be a role of bone homeostasis in CVD.  Additionally, in certain 
clinical populations, such as individuals with chronic kidney disease183 or diabetes212, the 
elderly213 and post-menopausal women214, both CVD and OP have a higher risk of occurring 
concurrently in the same individual. This suggests that there may be an underlying shared 
pathology between the two diseases. 
 In 2003, Doherty et al. reported that calcified regions of the arteries contain cellular 
components that are also normal constituents of bone215. The calcified cells appear to be able to 
differentiate into osteoblasts, or bone forming cells that are otherwise only apparently in bone216. 
Also, there is bone formation and resorption, by an osteoclast-like cell from a phagocytotic 
lineage217, within the calcified walls. Therefore, some have hypothesized that calcium deposition 
within the arteries occurs when the natural mechanism to inhibit this process is lost. In addition 
to the osteoblast and osteoclast-like cells, calcified plaques also contain other bone forming 
proteins such as bone morphogenetic-2, collagen, osteonectin, osteopontin, osteoclacin and 
osteoprotegerin (OPG)215.  
A major mechanism responsible for vascular calcium deposition is the OPG - receptor 
activator of nuclear factor kappa-β (RANK) - RANK-ligand (RANKL) pathway. In bone, 
RANKL is expressed on osteoblast cells and binds RANK on the surface of osteoclasts. This 
binding initiates osteoclast differentiation and activity. However, OPG is also expressed on 
osteoblast cells, including those in the vasculature. Osteoprotegerin blocks the binding of 
RANKL to RANK, leading to decreased bone resorption218. One of the earliest identifications for 
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a role of this pathway in vascular biology came from experiments in the OPG knockout mice, 
which develop vascular calcification in the renal and aortic arteries 219. 
However, there are additional mechanisms that may explain a correlation between CVD 
and OP. It seems obvious that there may be dysregulation of calcium as vascular calcification 
tracks with bone mineral loss. A misappropriation of calcium to the vasculature, rather than to 
the skeleton could explain this link, although how and why is unknown220.  Recently, a meta-
analysis reported that use of calcium supplementation, without combined vitamin D therapy, in 
women with or at risk for osteoporosis increases risk of cardiovascular disease221, which also 
may implicate calcium metabolism as a link between bone and CVD pathologies. 
 Also, there are characteristics common to both diseases, which may underlie the 
correlation, including chronic inflammation and sex steroids222. The increased risk of CVD and 
OP after the menopausal transition in women, provided the first suggestion that estrogen 
deficiency may be important in the like between CVD and OP216. Estrogens deficiency has long 
been associated with osteoporotic fractures, but it has more recently been shown that long-term 
exposure to estradiol may also lead to inflammation, insulin resistance and vascular 
calcification203. Oxidized lipids, which accumulate within the medial layer of arteries, are also a 
proposed link because they are known to increase CVD risk, as well as, slow bone formation223. 
Lastly, the regulation of the vascular endothelial lining is the first-line defense to CVD224. 
Endothelial function and tone are regulated by NO, which has recently been identified to be 
important in bone metabolism, although the exact mechanisms are unknown225. 
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2.5 SUMMARY 
Cardiovascular disease (CVD) is the leading cause of death in the US. Major risk factors for 
CVD include age, sex, ethnicity, hypertension, diabetes and dyslipidemia. Diet, obesity, exercise, 
tobacco use and alcohol consumption are among the most common, modifiable environmental 
factors affecting CVD risk; however, genetic factors are also well-recognized determinants of the 
disease process. African ancestry individuals have greater risk of CVD independent of traditional 
risk factors.  
Subclinical cardiovascular disease can be assessed using multiple non-invasive methods. 
Carotid ultrasound scans can identify plaques and subclinical atherosclerotic thickening of the 
vessel wall, as well as, measure of arterial diameter. Pulse-wave velocity is a non-invasive 
measure of arterial stiffening, or arteriosclerosis, which can be measured using automated 
tonometry devices. Pulse pressure is also a measure of central arterial stiffening and reflects the 
difference between systolic and diastolic blood pressures. Each of these measures is correlated 
with traditional risk factors for CVD and is predictive of future CVD events and mortality.  
In general, subclinical CVD traits tend to be heritable, with cIMT being the most widely 
studied measure in genetic studies. However, most studies of subclinical CVD genetics have 
been primarily in Caucasian populations, or in persons of admixed African descent, such as 
African Americans, rather than in homogeneous African samples. Given the difference in risk 
factor profiles and subsequent risk of disease in African ancestry populations, studies specifically 
characterizing the genetic contributions to subclinical atherosclerosis in homogeneous African 
ancestry populations are warranted.  
The association of bone mineral density and cardiovascular disease has been well 
documented and is thought to reflect more than an age-related epiphenomenon. Bone density has 
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been inversely associated with subclinical and clinical CVD, mainly in white populations, even 
after adjusting for potential confounding factors, such as age, body size, dyslipidemia, diabetes 
and hypertension. However, there has been little investigation of this link in populations of 
African ancestry. Studies in African ancestry individuals could provide additional and unique 
insight on the bone – CVD relationship since African ancestry populations tend to have stronger 
bones but greater CVD risk than their Caucasian counterparts. While there has been some 
experimental research on potential mechanisms for this relationship in animal models, there has 
been little genetic research in humans.  
Thus, the aims of this dissertation were threefold and conducted using extended pedigrees 
within a homogeneous, African ancestry sample in Tobago. First, we described CVD risk factor 
correlations with common carotid artery ultrasound traits (IMT, AD and LD). Additionally, we 
estimated their residual heritabilities and performed genome-wide linkage analysis of these traits 
after accounting for important covariates. Second, we described CVD risk factor correlations 
with arterial stiffness measures (PWV and PP), estimated their residual heritabilities and 
performed genome-wide linkage analysis of these traits. Lastly, we estimated the shared 
environmental and genetic effects on measures of subclinical CVD (IMT, AD and LD) and bone 
mineral density, bone geometry and bone strength. Where appropriate, bivariate, genome-wide 
linkage analyses were also used to identify potential chromosomal regions that contained genes 
with pleiotropic effects on CVD and bone related phenotypes. 
35 
2.6 TABLES 
Table 2.1 Carotid Intima-Media Thickness Heritability Studies 
Year Author Population Sample N 
Pedigree 
Type Trait 
h2r 
Estimate 
1996 Duggirala et. 
al.129 
Mexican City low-
income population 
88 Siblings CCA IMT 
ICA IMT 
0.92* 
0.86* 
2002 Lange et. al.125 EA and AA 
Diabetics in Forsyth 
County, NC, USA 
(Diabetes Heart 
Study) 
252 Siblings CCA IMT 0.41* 
2002 North et. al.122 American Indians 
(Strong Heart 
Family Study) 
887 Extended 
families 
CCA IMT 0.21* 
2002 Xiang et. al.116 Latino families with 
one hypertensive 
parent 
286 Nuclear 
families 
CCA IMT 0.34* 
2003 Fox et. al.128 EA offspring from 
the Framingham 
Heart Study 
1886 Siblings CCA IMT 
ICA IMT 
0.38* 
0.31* 
2003 Swan et. al.118 Scottish population 264 Twins Each wall 
individually  
Range:  
0.0-0.45 
2004 Juo et. al.127 High-risk Caribbean 
Hispanics (Northern 
Manhattan Family 
Study) 
440 Proband + 
1st degree 
relatives 
Total IMT 
CCA IMT 
Bif IMT 
ICA IMT 
0.36* 
0.39* 
0.26* 
0.12 
2005 Kao et. al.126 Mexican Americans 
(San Antonio Family 
Heart Study) 
620 Extended 
families 
CCA IMT 0.16* 
2005 Mayosi et. al.124 White British 
families with one 
hypertensive parent 
854 Nuclear 
families 
CCA IMT 0.24* 
2005 Moskau et. al.123 German families 
with one parent at-
risk for CVD 
565 Nuclear 
families 
CCA IMT 0.61* 
2005 Sayed-Tabatabei 
et. al.119 
Netherlander 
population (Erasmus 
Rucphen Family 
Study) 
930 Extended 
families 
CCA IMT 0.35* 
2005 Wang et. al.117 Mexican American 274 Nuclear CCA IMT 0.40* 
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Table 2.1 continued 
families with one 
parent with CHD 
families 
2006 Pilia et. al.113 Population-based 
Sardians (SardiNIA 
study) 
6049 Extended 
families 
CCA IMT 0.19* 
2008 Bowden et. al.114 EA and AA 
Diabetics in Forsyth 
County, NC, USAa 
973 EA 
175 AA 
Siblings CCA IMT 
(EA) 
CCA IMT 
(AA) 
CCA IMT 
(All) 
0.38* 
0.72* 
0.41* 
2008 Rampersaud et. 
al.121 
Old Order Amish 
families from 
Lancaster, PA, USA 
478 Siblings CCA IMT 0.29* 
2008 Zhao et. al.115  Male Vietnam 
veteran twins (Twin 
Heart Study) 
224 Twins Aggregate 
carotid 
IMT 
0.59* 
2009 Sacco et. al.120 High-risk Caribbean 
Hispanics (Northern 
Manhattan Family 
Study)b 
1390 Proband + 
1st degree 
relatives 
Total IMT 
CCA IMT 
Bif IMT 
ICA IMT 
0.65* 
0.56* 
0.58* 
0.47* 
* Heritability significant at P<0.05 
EA: European Americans; AA: African Americans; CHD: coronary heart disease; CCA: 
common carotid artery; ICA: internal carotid artery; Bif: bifurcation; IMT: intima-media 
thickness 
a Extension of study by Lange et. al. (2002) 
b Extension of study by Juo et. al. (2004)  
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Table 2.2 Pulse-Wave Velocity Heritability Studies 
Year Author Population Sample N 
Pedigree 
Type Trait 
h2r 
Estimate 
2005 Mitchell et. al.139 EA offspring from the 
Framingham Heart 
Study 
1480 Siblings cfPWV 0.40* 
2005 Sayed-Tabatabei 
et. al.119 
Netherlander 
population (Erasmus 
Rucphen Family 
Study) 
930 Extended 
families 
cfPWV 0.26* 
2006 Pilia et. al. 113 Population-based 
Sardians (SardiNIA 
study) 
6049 Extended 
families 
cfPWV 0.23* 
2007 Ge et. al.142 Population-based EA 
and AA twins 
(Georgia 
Cardiovascular Twin 
Study) 
702 Twins arPWV 
afPWV 
0.43* 
0.54* 
2007 Levy et. al.140 EA population-based 
sample (Framingham 
Heart and Offspring 
Studies)a 
644 Nuclear 
families 
cfPWV 
cbPWV 
0.43* 
0.02 
2008 Seidlerova et. 
al.141 
Caucasian European 
population (European 
Project on Genes in 
Hypertension) 
494 Nuclear 
families 
cfPWV 0.18 
2009 Cecelja et. al.143 Population-based 
Caucasian female 
twins (Twins UK 
cohort) 
496 Twins cfPWV 0.34* 
* Heritability significant at P<0.05 
EA: European American; AA: African American; cfPWV: carotid-femoral pulse-wave velocity; 
arPWV: aorto-radial pulse-wave velocity; afPWV: aorto-foot pulse-wave velocity; cbPWV: 
carotid-brachial pulse-wave velocity 
a Extension of study by Mitchell et. al. (2005) 
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Table 2.3 Pulse Pressure Heritability Studies 
Year Author Population Sample N 
Pedigree 
Type Trait 
h2r 
Estimate 
2001 Atwood et. al.150 Mexican Americans 
(San Antonio Family 
Heart Study) 
1770 Extended 
families 
bPP 0.21* 
2002 Adeyemo et. 
al.172 
Yorubans from 
population of Ibadan, 
Nigeria 
1825 Extended 
families 
bPP 0.13* 
2003 Camp et. al.171 Families of proband 
with early coronary 
heart disease from 
Utah, USA 
2444 Extended 
families 
bPP 0.25* 
2003 Snieder et. al.170 Population-based EA 
and AA twins (Georgia 
Cardiovascular Twin 
Study) 
534 Twins bPP 0.54* 
2003 DeStefano et. 
al.169 
EA population-based 
sample (Framingham 
Heart Study) 
1584 Nuclear 
families 
bPP 0.52* 
2003 Fava et. al.168 Population from 
Malmö, Sweden 
(Macrovascular and 
Hemodynamic Genetics 
Study) 
260 Siblings dabPP 
obPP 
0.53* 
0.21 
2005 Bielinski et. al.167 Black, Hispanic, Asian 
and White cohorts with 
hypertensive probands 
(Family Blood Pressure 
Program) 
10798 Nuclear 
families 
bPP 0.29* 
2005 Bochud et. al.166 East African families 
from Seychelles islands 
with ≥ 2 siblings with 
hypertension 
314 Nuclear 
families 
dabPP 
obPP 
0.54* 
0.37* 
EA and AA Diabetics 
in Forsyth County, NC, 
USA 
(Diabetes Heart Study) 
950 Siblings bPP 0.37* 
Hispanic and AA 
families (Insulin 
Resistance and 
Atherosclerosis Family 
Study) 
1856 Extended 
families 
bPP 0.34* 
2005 Hsu et. al.165 
(Reports results 
from three 
cohorts) 
Population-based 
sample of EA in USA 
(NHLBI Family Heart 
2761 Nuclear 
families 
bPP 0.27* 
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Table 2.3 continued 
  Study) 
2005 Mitchell et. al.139 Offspring from the 
Framingham Heart 
Study 
1480 Siblings cPP 0.35* 
2005 Turner et. al.164 Non-Hispanic whites 
from Rochester, Mn, 
USA (Genetic 
Epidemiology Network 
of Arteriopathy) 
488 Siblings bPP 0.29* 
2006 Pilia et. al.113 Population-based 
Sardians (SardiNIA 
study) 
6049 Extended 
families 
bPP 0.21* 
2006 Scurrah et. al.163 Volunteer sample of 
Australians (Victorian 
Family Heart Study) 
2911 Nuclear 
families 
bPP 0.20* 
2007 Van Rijn et. al.162 Netherlander 
population (Erasmus 
Rucphen Family Study) 
1006 Extended 
families 
bPP 0.24* 
2008 Franceschini et. 
al.161 
American Indians 
(Strong Heart Family 
Study) 
1892 Extended 
families 
bPP 0.25* 
2008 Seidlerova et. 
al.141 
Caucasian European 
population (European 
Project on Genes in 
Hypertension) 
494 Nuclear 
families 
bPP 0.02 
2009 Aberg et. al.160 Population-based 
sample from Samoan 
Islands 
1269 Extended 
families 
bPP 0.11* 
2010 Jelenkovic et. 
al.159 
Caucasian population-
based sample from the 
Greater Bilbao, Spain 
1302 Nuclear 
families 
bPP 0.14* 
2010 Kochunov et. 
al.158 
Mexican Americans 
(San Antonio Family 
Heart Study)a 
357 Extended 
families 
bPP 0.49* 
* Heritability significant at P<0.05 
EA: European American; AA: African American; bPP: brachial pulse pressure; dabPP: daytime 
ambulatory brachial pulse pressure; obPP: office visit brachial pulse pressure; cPP: central pulse 
pressure 
a Extension of study by Atwood et. al. (2001) 
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3.1 ABSTRACT 
Intima-media thickness (IMT) and arterial diameter (adventitial diameter [AD] and lumen 
diameter [LD]) predict cardiovascular disease and are determined in part by genetic factors. The 
genetic influence on these measures in African ancestry populations is not well defined.  
Therefore, we have estimated genetic heritability and performed genome-wide linkage analysis 
of carotid ultrasound traits in 7 large, multigenerational families of African ancestry from the 
Caribbean island of Tobago. Probands and families were recruited without regard to health 
status. A total of 395 individuals (mean family size 56; 2,392 relative pairs) aged ≥18 years, had 
an ultrasound scan of the common carotid artery. We estimated residual heritability and 
conducted multipoint quantitative trait linkage analyses using pedigree-based maximum 
likelihood methods. Significant covariates for all traits included age, sex, body size (BMI for 
IMT; height and waist circumference for diameter) and systolic blood pressure (treated 
hypertensives were excluded). After removing the effects of these covariates, residual 
heritabilities of mean IMT, max IMT, mean AD, max AD, mean LD and min LD were: 
0.47±0.11, 0.35±0.10, 0.64±0.12, 0.62±0.13, 0.58±0.12 and 0.57±0.12, respectively (all 
P<0.0001). Significant evidence of linkage (LOD > 3.3) was detected for max AD, mean LD and 
min LD on chromosome 11 (region max LOD=4.09, 133cM: max AD). Suggestive evidence for 
linkage, LOD >2.0, was detected for mean AD, mean LD and min LD on chromosome 14 
(region max LOD=2.50, 54cM: min LD) and for mean IMT and max IMT on chromosome 13 
(region max LOD=2.70, 115cM: mean IMT).  The linkage regions contain several genes known 
to be involved in cardiovascular disease including the ApoA1/C3/A4/A5 gene cluster, IL18, 
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BMP4, ESR2 and SMOC1.  Further studies of these regions may reveal novel insight into the 
genetic regulation of carotid ultrasound traits and atherosclerosis in African ancestry individuals. 
3.2 INTRODUCTION 
Cardiovascular disease (CVD) is a complex, multifactorial disease, which aggregates in families.  
It is the largest cause of mortality in Western societies2, 3.  Factors influencing disease 
susceptibility include increased age, male gender, body mass index (BMI), hypertension, high 
LDL cholesterol and triglyceride levels, low HDL cholesterol levels, diabetes mellitus and 
family history, among others8, 12-14.  Carotid intima-media thickness (IMT) is a non-invasive, 
reproducible measure of arterial wall response to blood flow and subclinical atherosclerosis33.  It 
is strongly correlated to atherosclerosis in multiple arterial beds and predictive of subsequent 
stroke, myocardial infarction and mortality33, 34, 44.  Additionally, larger adventitial diameter 
(AD) and smaller lumen diameter (LD) are also predictive of future cardiovascular risk23, 51.  
Each of these physiologic measures can be easily obtained for the carotid artery using ultrasound 
technologies33.   
Heritability estimates the genetic influence on a disease or phenotype using samples of 
related individuals such as families, siblings or twins111, 226.  Many studies have reported 
statistically significant heritability of carotid IMT with estimates that range from 0.25-0.92115-119, 
121-129, with the majority of estimates between 0.30-0.40, after adjustment for various CVD risk 
factors. This suggests that there is a genetic component to carotid wall thickness. However, 
heritability estimates were derived from multiple samples with diverse ethnic backgrounds, 
including studies using mixed ethnicities. There have been no studies, to date, reporting on the 
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heritability of carotid artery phenotypes in a homogeneous, African ancestry population. Also, 
little is known about the heritability of other carotid ultrasound-derived measures of subclinical 
atherosclerosis, such as AD, although one study suggests that the heritability of AD may be 
greater than that of IMT122. 
Genome-wide linkage analyses have identified quantitative trait loci (QTL) for carotid 
IMT on chromosomes 2117, 7120, and 12132. A region on chromosome 12p has been replicated in 
an independent population-based cohort130. However, none of these linkage studies have been 
conducted in a collection of exclusively African ancestry families. Only a study by Bowden et. 
al. (2008) that included Caucasian and African American families found evidence of linkage 
(LOD=4.39) for calcified plaque in a region of chromosome 16p. However, this study found no 
evidence of linkage with IMT (all LOD<2.0) in the total sample or in the subset of African 
American families114.  
 Additionally, many genome-wide association and candidate gene studies have found 
associations between subclinical atherosclerosis and the 9p21.3 region 136, 156, 157. Other genes 
that have been studied in large populations with relation to carotid ultrasound traits in humans 
include APOE, ACE, MTHFR, NOS3 and ADD1 but only APOE has shown consistent and 
convincing evidence of association133. Therefore, we estimated the genetic heritability of carotid 
IMT, AD and LD in a well-characterized sample of large, multigenerational families of African 
ancestry from the Caribbean island of Tobago. We also used a genome-wide linkage panel of 
single nucleotide polymorphism (SNPs) to identify QTL peaks for carotid ultrasound phenotypes 
in these families. 
44 
3.3 MATERIALS AND METHODS 
3.3.1 Study Sample 
Participants for this analysis were from the Tobago Family Health Study. Briefly, 8 probands 
were recruited without regard to their medical history from a cohort study of bone mineral 
density and body composition on the Caribbean island of Tobago4. Probands were eligible if they 
had a spouse willing to participate and had at least six living offspring and/or siblings aged ≥18 
years and who were residing in Tobago. All first-, second-, and third-degree relatives of the 
probands and their spouses were invited to participate. To date, we have recruited 471 
individuals belonging to 7 large families. The families consisted of: 21, 26, 28, 49, 96, 98 and 
153 individuals (mean = 67 individuals) and 4,206 relative pairs. The sample consists of 283 
women and 188 men aged 18-103 years (mean age, 43 years).  
An ancillary study in 2007 invited all participants to complete a carotid ultrasound scan.  
There were 415 participants who returned (88% of survivors) and completed the carotid scan.  
We have analyzed the data from ultrasound images from 395 of these individuals (152 men and 
243 women) who form the basis for the current analyses. Written informed consent was obtained 
from each participant. The Tobago Division of Health and Social Services and the University of 
Pittsburgh Institutional Review Boards approved this study. 
3.3.2 Carotid Ultrasound 
The common carotid artery was imaged with B-mode ultrasonography using an Acuson Cypress 
portable ultrasound machine (Siemens Medical Solutions, Malvern, PA). Both the near and far 
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walls of the distal common carotid artery were captured for one centimeter proximal to the 
carotid bulb. Only the common carotid artery could be imaged with the portable technology. 
Intima-media thickness (IMT) was obtained using a semi-automated reading software system 
(AMS system; Dr. Thomas Gustavsson, Sweden). This system detects and traces lines, with 
reader input, between the lumen-intima and media-adventia borders across the 1 cm segment. 
Then, the software generates one thickness measurement per pixel across this area, for about 140 
measures in total. Mean IMT measures correspond to the mean IMT across all pixels of both the 
near and far wall of the common carotid artery on both the right and left arteries. The mean max 
IMT measures the maximum thickness per wall, per side and then is recorded as the mean of 
those four maxima. Adventitial and lumen diameter measures were obtained from the same 1 cm 
region and correspond to the distance between near and far wall medial-adventitial borders and 
the distance between the near and fall wall luminal-medial borders, respectively. Both sides of 
each participant were averaged to obtain the mean AD or LD measure. Similar to IMT, the mean 
max AD corresponds to the mean of the largest diameter measure for each side of the participant, 
while the mean min LD corresponds to the mean of the smallest diameter measure for each side 
of the participant. All images were read centrally at the Department of Epidemiology’s 
Ultrasound Research Laboratory (University of Pittsburgh, Pittsburgh, PA). Reproducibility 
analyses were conducted on 35 Tobago Family Health Study participants. The inter-sonographer 
intraclass correlation (ICC) was 0.97 for mean IMT and 0.95 for mean AD. Inter-reader ICC was 
0.99 for mean IMT and mean AD. 
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3.3.3 Other Measures 
Cardiovascular risk factors available for this analysis included age, sex, height, waist 
circumference, BMI, current smoking, alcohol intake, walking for exercise, diabetes, 
hypertension, menopausal status, parity, oral contraceptive use, serum lipid and lipoprotein 
concentrations, systolic blood pressure, use of anti-hypertensive medication and heart rate. Body 
weight was measured to the nearest 0.1 kg on a balance beam scale. Standing height was 
measured to the nearest 0.1 cm, without shoes, using a wall-mounted stadiometer. Waist 
circumference at the top of the hipbone was measured to the nearest 0.1 cm. Body mass index 
was calculated as weight in kg divided by standing height in meters2.  
Demographic, lifestyle and medical history variables were collected by trained clinic staff 
through administration of a questionnaire and interview. Race was based on self-report of 
grandparental ethnic origin. The Tobago population is predominately of West African origin 
with low admixture6. Smoking status was classified as either current or not (yes/no), and 
participants reporting smoking <100 cigarettes in their lifetime were considered non-smokers. 
Alcohol consumption was assessed by questionnaire and coded as having >1 drink per week 
(yes/no) because there was a very low prevalence of substantial alcohol intake. Physical activity 
was assessed by the number of minutes walked per week and participants were dichotomized 
into “not active” or “active” determined by a median split (≤25 minutes walked/week vs. >25 
minutes walked/week, respectively). Participants were asked to bring current medications to their 
interview, and staff recorded each medication.  Diabetes was defined as a fasting glucose level 
≥126 mg/dl or current use of diabetes medication. Hypertension was defined as a seated diastolic 
blood pressure ≥90 mmHg, systolic pressure ≥140 mmHg and/or current use of anti-hypertensive 
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medication. For analyses including systolic blood pressure measures, we excluded individuals on 
anithypertensive medication (n=31). 
 Reproductive characteristics included menopausal status, parity, oral contraceptive (OC) 
use and hormone replacement therapy (HRT). Because only 5/283 women reported using HRT, 
this variable was not included in this analysis. Women were considered postmenopausal only if 
they had no menses for at least 12 months and were >40 years old, or if they had a hysterectomy 
or ovariectomy.  
3.3.4 Lipid Measures 
A fasting blood sample was collected at the time of interview. Serum samples were separated 
and stored at -80°C until time of assay. Lipid measures (LDL-c, HDL-c and triglycerides) were 
assessed in the Heinz Nutrition Laboratory at the University of Pittsburgh’s Graduate School of 
Public Health, which has met the accuracy and precision standards of the Centers for Disease 
Control and Prevention and is CLIA certified. HLD-c was determined using the selective 
heparin/manganese chloride precipitation method. LDL-c was calculated by means of the 
Friedewald equation. Triglycerides were determined enzymatically using the procedure of 
Bucolo and David227. 
3.3.5 Genotyping and Multipoint Identity-by-Descent (IBD) Calculation 
Genomic DNA was isolated from whole blood extracted by the salting out method and isolated 
by a Qiagen column procedure (Qiagen, Santa Clara, CA). Whole-genome genotyping by 
fluorescence-based methods was performed using the Infinium HumanLinkage-12 Genotyping 
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BeadChip (Illumina, San Diego, CA). After excluding single nucleotide polymorphisms (SNPs) 
with call rate <90%, Hardy-Weinberg equilibrium (P<0.001), minor allele frequency <0.05 or 
multipoint IBD calculation incompatibility, we retained 1512 autosomal SNPs and used the 
Markov chain Monte Carlo algorithm as implemented in the program Loki228 to calculate 
multipoint IBD. The final SNP set had a median MAF of 0.325 with a median spacing of 1.92 
cM based on the Kosambi mapping function229. 
3.3.6 Statistical Analysis 
Variance components (VC) analysis determines the proportion of variation in a particular trait 
that is attributable to environmental and genetic factors. The Sequential Oligogenic Linkage 
Analysis Routines (SOLAR) program112 employs VC methods to account for the genetic 
structure within the data using pedigree information. The VC methods within SOLAR not only 
control for this structure, but also estimate the proportion of the trait variation that is attributable 
to genetic, covariate (environmental) and error effects111, 112, 230. The model tested by SOLAR is 
as follows: Yi = μ + gi + Σβkzik + ei where μ is the overall trait mean, gi is the genetic component, 
Σβkzik is the summation of all modeled covariate (environmental) effects and ei is the residual 
unmodeled variation (error) in trait Yi112, 230. 
All traits were assessed for non-normality and transformed as necessary. Outliers, defined 
as ≥4 SD from the mean, were removed for each trait; no more than 2 observations were 
removed from any ultrasound trait. To determine significant correlates of ultrasound traits, we 
tested each covariate separately using the VC framework in SOLAR. We first developed an age 
and sex adjusted model for each trait. Age and sex were forced into all subsequent models 
because they are established correlates of subclinical atherosclerosis. All potentially significant 
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covariates (P<0.10) were then assessed simultaneously for each trait. We required a p-value 
<0.05 for inclusion in our final models. 
Maximum likelihood methods were used to simultaneously model the effect of additive 
genetics, or heritability (h2), fixed covariate effects and error. Heritability reported herein is the 
residual heritability (h2r), which is estimated as the proportion of phenotypic variation after the 
effects of covariates. We also used SOLAR to estimate the residual heritability (detailed in 
Section 3.2.1) and the variance attributable to the fixed covariate effects for each ultrasound trait. 
To compare the effects of covariates across all traits, we calculated the percent difference 
in the ultrasound trait per unit increase in covariate. Percent differences were calculated as beta 
coefficient*unit/mean trait value*100. For continuous variables, the unit range was 1 SD, and for 
dichotomous variables, the unit range was 1.  
Multipoint linkage analysis was used to identify genomic regions that were inherited with 
the ultrasound traits. Linkage is based on the sharing of genetic material between generations as 
identity-by-descent (IBD), that is, for any given genetic locus, a family pair can either have 
received one allele from a common ancestor or neither of the alleles from a common ancestor. 
Only siblings can have both of their alleles from the same ancestors (eg. the same allele from 
their father and the same allele from their mother).  
 Quantitative trait linkage analysis estimates the variance in a continuous trait attributable 
to a theoretical quantitative trait locus (QTL). Linkage tests the assumption that within a QTL 
responsible for a trait’s variance, the traits are more similar between persons that share more of 
their genetic information at that locus IBD than those that do not. Multipoint IBD probabilities 
are used to assess IBD sharing along each chromosome. The significance of the theoretical QTL 
was tested with a likelihood ratio test at 1 cM intervals across each autosomal chromosome. 
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Maximum likelihood methods tested whether the model containing a parameter for the 
theoretical QTL was more likely than the model incorporating only polygenic effects. Logarithm 
of the odds (LOD) scores, computed as the log10 of the likelihood ratio, were used to assess the 
significance of the test. LOD score thresholds of 3.3 and 2.0 were considered to represent 
nominal genome-wide significant and suggestive evidence for QTLs, respectively231. 
Computational power previously limited the feasibility of these analyses for some pedigrees; 
however, using SOLAR112, 232 this is now possible in extended, complicated pedigrees such as 
those from the Tobago Family Health Study, and is robust to type 1 error and has more power 
than traditional nuclear family linkage analyses233, 234. 
3.4 RESULTS 
3.4.1 Family Study Characteristics 
The characteristics of the Tobago Family Health Study participants are displayed in Table 3.6.1 
for the whole sample, as well as, for men and women, separately. The sample is fairly young 
with a mean age of 42 years (range 18-86 years). This population is overweight on average, with 
a mean BMI of 28.4 kg/m2. Women were significantly more overweight than men (BMI: 29.3 
kg/m2 versus 26.7 kg/m2; P<0.0001). Even though women have a higher BMI than men, there 
was no significant difference in central adiposity, as assessed by waist circumference. As 
expected, men were significantly taller than women (177.1 cm vs. 166.4 cm, P<0.0001). They 
also had a much higher frequency of current smoking and alcohol consumption than women.  
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The prevalence of diabetes and hypertension were 8.3% and 26.6%, respectively. Women 
were more likely to be on antihypertensive medication than men (11.1% vs. 4.0%, P=0.012). 
Among individuals not on antihypertensive medication, women had lower systolic blood 
pressure (SBP) than men (114.1 mmHg vs. 125.7 mmHg, P<0.0001). LDL-c was ~10mg/dl 
greater in women than men (P=0.033), but there was no significant difference in HDL-c between 
sexes. Triglycerides were ~12mg/dl greater in men than women (P=0.019).  
 Characteristics of the carotid ultrasound traits are shown in Table 3.6.1 as well as in 
Figure 3.6.1. The carotid vessel walls were thin on average (mean IMT: 0.69 mm), but this was 
not unexpected in this relatively young population. IMT was similar in men and women overall 
and within 10-year age strata (Figure 3.6.1).  IMT increased with age in both sexes. However, 
men had larger arterial diameters compared to women overall (P<0.0001 for AD and LD). 
Adventitial diameter and LD tracked similarly across 10-year age groups with women having 
much smaller diameters then men, especially in the younger age groups (not adjusted for height). 
Both diameter measures increased progressively across age groups in men. In contrast, arterial 
diameter measures were relatively stable in younger women but increased among women aged 
50 years and older. 
3.4.2 Environmental Correlates of Carotid Ultrasound Traits 
Cardiovascular risk factors that were correlated with carotid ultrasound traits are described in 
Table 3.6.2. We first investigated the association between traditional risk factors and carotid 
ultrasound traits adjusted for age and sex. Factors of interest included BMI, height, waist 
circumference, current smoking, alcohol intake, walking, diabetes, hypertension, SBP, LDL-c, 
HDL-c and triglycerides. There were relatively few factors that were correlated with the carotid 
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traits in these families. The final models were similar for all traits including measures of age, 
sex, body size and SBP. Only age, sex, BMI and SBP were significant independent correlates of 
IMT. Height was not a significant correlate of IMT, but was significantly related to artery 
diameter. Only age, sex, height, waist circumference and SBP were significant independent 
correlates of AD and LD.  
Age, BMI and SBP were positively correlated with IMT. For every five-year increase in 
age, IMT increased by 3-4%. For every standard deviation increase in BMI (6.4 kg/m2), mean 
IMT increased by 1.4% and mean maximum IMT increased by 2.5%. For every standard 
deviation increase in SBP (21.8 mmHg), mean IMT increased 1.9% and mean maximum IMT 
increased by 3.4% (all P<0.01). Female sex was inversely correlated with IMT such that women 
had 1.9% thinner mean IMT (P<0.05), but sex was not significantly associated with maximum 
IMT measures.  
 Adventitial diameter was also correlated with age, sex and SBP in the same directions as 
IMT, although the associations with sex were not significant and the effect of age on increasing 
vessel diameter was not as strong (less than 1% per 5 year age increase versus 3-4% for IMT). 
Each standard deviation increase in height and waist circumference was associated with a 2% 
increase in AD (P<0.01). Lumen diameter had nearly the exact same covariate effect associations 
as AD, except that age was inversely associated with LD (P<0.05). 
3.4.3 Variance Components of the Carotid Ultrasound Traits 
The proportion of carotid ultrasound trait variance attributed to covariates and additive genetic 
effects are shown in Table 3.6.2. Covariates accounted for more of the variance in maximum and 
minimum traits compared with mean traits, and they also explained more than twice the variance 
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in IMT than in diameter traits (r2: mean IMT = 0.552, mean max IMT = 0.564, mean AD = 
0.242, mean max AD = 0.270, mean LD = 0.169, mean min LD = 0.182). There was significant 
residual heritability (h2r) for each trait after adjusting for the effects of covariates (P<0.0001 for 
all). Heritabilities were higher for mean traits than for maximum or minimum traits, and they 
were larger for diameter traits than for IMT traits (h2r: mean IMT = 0.467; mean max IMT = 
0.349; mean AD = 0.641; mean max AD = 0.622; mean LD = 0.584; mean min LD = 0.573). 
3.4.4 Linkage Analysis of Carotid Ultrasound Traits 
Results of the linkage analysis of the ultrasound traits adjusted for the significant covariates are 
summarized in Table 3.6.3 and depicted in Figures 3.6.2 and 3.6.3. All peak LOD scores that 
were at least suggestive of linkage (LOD ≥ 2) with a carotid ultrasound trait are listed in Table 
3.6.3. Evidence for significant linkage (LOD > 3.3) was identified around 134 cM on 
chromosome 11. The greatest LOD score was 4.09 for mean maximum AD. A nearly identical 
peak was identified for mean LD (LOD = 4.06) and mean minimum LD (LOD = 3.82). No other 
peak LOD scores were greater than 3.3. However, there were an additional seven, peak LOD 
scores ≥ 2.0. Mean AD also had a peak suggestive of linkage at the same region of chromosome 
11 (LOD = 2.22). Mean AD, mean LD and mean minimum LD had peak LOD scores suggestive 
of linkage around 55 cM on chromosome 14 (LOD = 2.48, 2.17 and 2.50, respectively). Mean 
and mean maximum IMT had peak LOD scores suggestive of linkage around 114 cM on 
chromosome 13 (LOD = 2.70 and 2.18, respectively). 
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3.5 DISCUSSION 
We examined carotid ultrasound phenotypes in a sample of multi-generational African ancestry 
families who represent a unique sample for whom these traits have not been described 
previously. We found that all carotid traits had significant residual heritability after accounting 
for important covariates including several major CVD risk factors. Residual heritability was 
greater for vessel diameters compared with IMT. We also identified a region on chromosome 11 
in linkage with diameter measures in these families.   
In accordance with previous reports in predominantly non-African ancestry families115-
119, 121-129, IMT was significantly heritable after adjustment for significant covariates. Covariates 
explained more than 50% of the variance in IMT, suggesting that while there were few 
significant covariates, they had a substantial influence on IMT. Covariates explained only ~20-
40% of the variance in arterial diameter measures, but the estimates of heritability were larger 
then those for IMT. This suggests that the genetic component is more influential than the 
modeled covariates in determining arterial diameter. 
Using a genome-wide panel of SNPs, we tested for linkage with carotid ultrasound traits. 
We identified a region in linkage with arterial diameter located at approximately 133 cM on 
chromosome 11. The peak LOD score was just over 4.0 for both maximum AD and mean LD. 
Adventitial diameter is thought to be an early adaptation to hemodynamic changes partially 
associated with atherosclerosis, whereas lumen diameter expands with AD initially, but then 
narrows in the later stages of atherosclerosis 10, 11. This linkage region spans ~20 Mbp and 
contains 79 known genes. Interestingly, this genomic region contains the ApoA1/C3/A4/A5 gene 
cluster and the IL18 gene. The apolipoprotein gene cluster encodes apolipoproteins A and C, 
which aid in lipid transport 235. Allelic variation in these genes has been associated with lipid 
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levels236-244. In particular, the associations between ApoA5 and triglyceride levels237, 238 and 
ApoA1 and HDL cholesterol levels243 have been replicated in multiple populations including 
genome-wide association studies236. Lipid profiles are notably more favorable in African 
ancestry populations than in Caucasians, yet their overall rates of CVD are higher1, 3. Further 
research on the apolipoprotein gene cluster and carotid phenotypes in these families may reveal 
important insight into the genetic regulation of subclinical atherosclerosis in African ancestry 
individuals. 
The interleukin-18 (IL18) gene has been studied in multiple populations for association 
with clinical and subclinical CVD. Interleukin 18 is a proinflammatory cytokine245 that has been 
associated with myocardial dysfunction and coronary events246. Genetic variation in the promoter 
of the IL18 gene has been associated with serum IL18 levels, which were predictive of coronary 
events 247. Genetic variation in IL18 has also been associated with hypertension248, 249, 
diabetes250, 251, subclinical CVD252 and coronary artery disease 247, 253, 254. Given these previous 
findings, the IL18 gene region is also a candidate locus of interest under our linkage peak. 
However, we cannot exclude other potentially important genes such as TAGLN, which controls 
in part vascular smooth muscle cell migration255, 256; SCN2B, which has been associated with 
atrial fibrillation257; IL10RA, which is involved in the inflammatory response in carotid 
plaques258; and NNMT, which may control homocysteine levels259. 
We also found suggestive evidence of linkage on chromosome 14 with arterial diameters. 
The max LOD was 2.50 for minimum LD at 54 cM on chromosome 14. This linkage peak spans 
a ~22 Mbp region of the genome and contains 137 known genes. There are no widely studied 
cardiovascular genes in the region so it is difficult to hypothesize the best genes for follow-up. A 
few genes had some evidence of involvement in the atherosclerotic process, including BMP4, 
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ESR2, SMOC1, LGALS3 and GCH1. Bone morphogenetic protein 4 (BMP4) has been identified 
as a protein involved in vascular calcification260 and vascular endothelial response to blood flow 
stress261, and could be an interesting candidate gene for atherosclerosis. However, there are no 
previous genetic studies in humans to support a genetic association. Also, estrogen receptor 2 
(ESR2) controls levels of circulating estrogens, which are associated with atherosclerosis262. 
Previously, genetic variation in this gene has been associated with subclinical CVD153, 262. 
SMOC1, a secreted calcium binding protein, was suggested by Sherva et. al., who, in performing 
a linkage scan for pulse pressure in African Americans, also found a peak suggestive of linkage 
overlapping our peak on chromosome 14263. The genes LGALS3 and GCH1 could also be 
candidate genes for their control of lipids264 and oxidative stress265, respectively. 
The only peak suggestive of linkage for IMT was on chromosome 13, spanned 7.5 Mbp, 
and contained 22 known genes. Of these 22 genes, only one has been associated with CVD 
(SLC10A2). SLC10A2 encodes a bile acid transporter that is expressed mainly in the ileum and 
the kidney266. There is evidence that disruption of the gene/protein can lead to primary bile acid 
malabsorption or familial hypertriglyceridemia resulting in changes in serum cholesterol 
levels267, 268. 
Many, previous genome-wide linkage scans for CVD traits have identified genomic 
regions that may have some control over CVD progression and outcomes. The most widely 
reported and replicated region is at chromosome 9p21.3156, 157, which was not replicated in the 
current study. The region on chromosome 14 identified in this study has been identified in a 
genome-wide linkage scan (Sherva et. al.263) of pulse pressure/stroke volume ratio in the African 
American HyperGEN study. This index is related to short-term arterial diameter and may suggest 
that the region we identified on chromosome 14 may control short-term arterial response to 
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blood flow, rather than a change in arterial diameter due to atherosclerotic plaques. In fact, when 
our data was not adjusted for systolic blood pressure, the linkage signal on chromosome 14 
reached a significant, maximum LOD of 3.8 (data not shown), but was only suggestive of 
linkage after complete adjustment (LOD = 2.5). 
The carotid artery walls in our study sample were thin (mean = 0.69 mm), suggesting that 
the atherosclerotic burden in these families is low. Similar covariates were associated with IMT 
and arterial diameter traits, including age, sex, body size and systolic blood pressure. Many other 
risk factors that have been associated with CVD in other African ancestry populations46, 47 were 
assessed, such as smoking, diabetes, dyslipidemia and other lifestyle factors, but none were 
significantly related to carotid ultrasound phenotypes. This apparent inconsistency in findings 
could reflect differences in the characteristics of the populations studied. For example, our 
sample was young and had relatively healthy arteries with little evidence of atherosclerosis. 
 In conclusion, carotid artery phenotypes including measures of IMT, AD and LD, are 
under significant genetic control in this sample of African ancestry individuals. Each trait was 
significantly associated with age, body size, and systolic blood pressure, but not related to other 
traditional cardiovascular disease risk factors such as smoking, dyslipidemia and diabetes. By 
using a moderately dense genome-wide SNP panel, we were able to identify a genomic region on 
chromosome 11 that is responsible for a significant proportion of the genetic variance in arterial 
diameter. This region contains multiple genes that may be involved in atherosclerotic disease 
process and may warrant further research. 
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3.6 TABLES AND FIGURES 
Table 3.1 Characteristics* of the Afro-Caribbean Families 
Trait All (n=395) 
Men 
(n=152) 
Women 
(n=243) 
Age (years) 42.1 ± 15.7 42.2 ± 15.4 42.1 ± 15.9 
BMI (kg/m2) 28.4 ± 6.3 26.8 ± 5.1‡ 29.5 ± 6.7‡ 
Height (cm) 170.5 ± 8.3 177.1 ± 6.8 166.4 ± 6.3‡ 
Waist Circumference (cm) 89.7 ± 15.3 90.3 ± 12.9 89.4 ± 16.7 
Current Smoker (%) 4.3 10.7‡ 0.4‡ 
>1 Drink per week (%) 12.7 29.1‡ 2.5‡ 
≥25 Min walk per week (%) 48.5 53.0 45.7 
Diabetes (%) 8.3 6.4 9.4 
Hypertension (%) 26.6 27.8 25.8 
Hypertensive Medication (%) 8.4 4.0‡ 11.1‡ 
Systolic Blood Pressure (mmHg)§ 118.8 ± 21.8 125.7 ± 19.5 114.1 ± 22.1‡ 
Heart Rate (beats/min) 72.2 ± 12.1 66.7 ± 12.4‡ 74.4 ± 11.4‡ 
LDL-c (mg/dl) 132.8 ± 40.1 126.9 ± 37.5‡ 136.5 ± 41.3‡ 
HDL-c (mg/dl) 39.8 ± 12.3 40.7 ± 11.6 39.2 ± 12.7 
Triglycerides (mg/dl) 88.9 ± 44.9 96.2 ± 54.1‡ 84.5 ± 37.6‡ 
Menopausal (%)† 30.1 -- 30.1 
Parity (%)† 77.0 -- 77.0 
Oral Contraceptive (%)† 34.4 -- 34.4 
Mean carotid IMT (mm) 0.69 ± 0.15 0.70 ± 0.15 0.68 ± 0.14 
Mean max carotid IMT (mm) 0.80 ± 0.17 0.81 ± 0.17 0.79 ± 0.16 
Mean AD (mm) 7.23 ± 0.72 7.49 ± 0.68‡ 7.07 ± 0.70‡ 
Mean max AD (mm) 7.53 ± 0.76 7.78 ± 0.74‡ 7.36 ± 0.74‡ 
Mean LD (mm) 5.86 ± 0.64 6.09 ± 0.63‡ 5.71 ± 0.61‡ 
Mean min LD (mm) 5.65 ± 0.64 5.89 ± 0.62 5.51 ± 0.61‡ 
*Characteristics are shown as mean ± SD or frequency (%) 
§Excluding participants on antihypertensive medication 
†Frequency in women only 
‡Comparison by sex is statistically significant (p<0.05) 
IMT: intima-media thickness; AD: adventitial diameter; LD: lumen diameter 
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Table 3.2 Significant Covariate Associations and Residual Heritability of Carotid Ultrasound Traits 
Proportion of Trait Variance 
Trait Age (5 years) 
Female 
Sex 
BMI 
(6.3 kg/m2)
Height 
(8.3 cm) 
Waist 
Circumference 
(15.3 cm) 
Systolic Blood 
Pressure 
(21.8 mmHg) 
Covariate 
Effects (r2) 
Genetic Effects 
(h2r ± SE)¥ 
Mean IMT 2.6%§ -1.9%† 1.4%‡   1.9%‡ 0.552 0.467±0.110 
Mean Max IMT 4.1%§ -2.7% 2.5%‡   3.4%§ 0.564 0.349±0.101 
Mean AD 0.5%‡ -2.1%  2.0%‡ 1.8%§ 2.2%§ 0.245 0.641±0.120 
Mean Max AD 0.6%§ -2.0%  2.0%‡ 1.9%§ 2.1%§ 0.270 0.622±0.127 
Mean LD -0.4%† -2.1%  2.5%‡ 2.1%‡ 1.8%‡ 0.169 0.584±0.123 
Mean Min LD -0.5%† -2.2%  2.7%‡ 2.1%‡ 1.8%‡ 0.182 0.573±0.120 
Values shown by covariate depict the percent change in carotid ultrasound trait value for each unit change in covariate value. Unit 
values are 1 for dichotomous values and are shown in parentheses for continuous values. IMT: intima-media thickness; AD: 
adventitial diameter; LD: lumen diameter 
¥ All residual heritability estimates had a corresponding P<0.0001 
†P<0.05 
‡P<0.01 
§P<0.0001 
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Table 3.3 Genome-Wide Linkage Results for Carotid Ultrasound Traits 
QTL Location§ Genes in Region 
Trait* Peak LOD Chr cM (range) Cytogenetic Base Position (Mbp) N 
Potential 
Candidate Genes 
of Interest 
Mean IMT 2.702 13 115 (105-119) q32.3-q33.3 99.6-106.9 22 SLC10A2 
Max IMT 2.179 13 113 (104-121) q32.3-q33.3 99.6-107.1 22 SLC10A2 
Mean AD 2.478 14 55 (45-66) q22.1-q24.2 48.6-70.2 133 BMP4; ESR2 
Mean AD 2.217 11 133 (131-136) q23.1-q23.2 110.2-113.3 27 IL18 
Max AD 4.089 11 134 (130-146) q23.1-q23.3 110.2-117.4 
55 APOA1/C3/A4/A5 
cluster; IL18 
Mean LD 4.056 11 133 (128-149) q22.3-q23.3 108.5-117.4 
58 APOA1/C3/A4/A5 
cluster; IL18 
Mean LD 2.174 14 54 (45-67) q22.1-q24.2 48.6-70.7 137 BMP4; ESR2 
Min LD 3.824 11 133 (128-152) q22.3-q23.3 108.5-118.5 
79 APOA1/C3/A4/A5 
cluster; IL18 
Min LD 2.500 14 54 (45-65) q22.1-q24.1 48.6-68.8 123 BMP4; ESR2 
Only regions with a peak LOD ≥ 2.0 are shown. 
IMT: intima media thickness; AD: adventitial diameter; LD: lumen diameter; Chr: chromosome 
*All analyses were adjusted for covariates listed in Table 3.6.2 above 
§Location defined by the position of the peak LOD±1.0 where peak LOD<3.0 and defined as 
LOD±2.0 where peak LOD≥3.0 
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Figure 3.1 Carotid Ultrasound Traits by Age and Sex 
Mean and standard errors of intima-media thickness (a), adventitial diameter (b) and lumen 
diameter (c) by 10-year age group for men (grey) and women (black), separately. IMT: intima-
media thickness; AD: adventitial diameter; LD: lumen diameter 
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Figure 3.2 Genome-Wide Linkage LOD Scores for Carotid Ultrasound Traits 
Multipoint LOD scores at each cM across the genome plotted for each ultrasound trait: intima-
media thickness (a.), adventitial diameter (b.) and lumen diameter (c.). Dotted line at LOD=2.0 
signifies suggestive evidence of linkage threshold. Dotted line at LOD=3.3 indicates significant 
evidence of linkage threshold. Black line=mean traits; Grey line=mean of the maximum (intima-
media thickness and adventitial diameter) or minimum (lumen diameter) traits. 
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Figure 3.3 Chromosomes with Regions Suggestive of Linkage 
Multipoint LOD scores at each cM across chromosome 13 (a.), 11 (b.) and 14 (c.) are plotted for 
IMT (a.) and diameter (b. and c.) traits. IMT: intima-media thickness; AD: adventitial diameter; 
LD: lumen diameter. 
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4.1 ABSTRACT 
Pulse pressure (PP) and pulse-wave velocity (PWV) are measures of arterial stiffness that are 
predictive of cardiovascular disease events. Arterial stiffness is partially a result of hypertension, 
which is more prevalent in African ancestry populations than any other ethnicity. We have 
estimated the genetic heritability of and performed genome-wide linkage analysis of PP and 
PWV in 7 large, multigenerational families of African ancestry from the Caribbean island of 
Tobago.  Probands and families were recruited without regard to health status.  A total of 361 
individuals (mean family size 52; 2,549 relative pairs) aged ≥18 years had non-invasive 
waveform analysis at the brachial and ankle (tibial) arteries to determine brachial systolic blood 
pressure (SBP) and diastolic blood pressure (DBP), brachial PP and brachial-ankle PWV. We 
estimated residual heritability and conducted multipoint quantitative trait linkage analyses using 
pedigree-based maximum likelihood methods. Significant covariates included age, sex, body size 
(BMI for SBP, DBP and PP; height and weight for PWV), heart rate, menopause (PP only) and 
diabetes (PWV only). Pulse pressure and PWV increased with age and were greater in men than 
women. Residual heritabilities of SBP, DBP, PP and PWV were: 0.29, 0.40, 0.27 and 0.24, 
respectively (all P<0.05). Suggestive evidence of linkage (LOD > 2.0) was detected for PP on 
chromosome 5 (max LOD=2.55, 35cM), replicating a previous genome-wide association study 
for subclinical cardiovascular disease. Further studies of this region may reveal novel insight into 
the genetic regulation of arterial stiffness. 
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4.2 INTRODUCTION 
Cardiovascular disease (CVD) is the number one cause of death in the United States and it is 
estimated that more than 1 of every 3 Americans has some type of prevalent CVD, including 
hypertension, heart failure, coronary heart disease or stroke1. Identifying individuals at risk for 
CVD early in life is key to prevention and treatment efforts. With age, arteries gradually stiffen, 
which leads to faster pressure waves, thus, increasing systolic blood pressure and prevalence of 
isolated systolic hypertension20. Subclinical measures of arterial stiffness, such as pulse pressure 
(PP) and pulse-wave velocity (PWV), are used to assess risk of future clinical disease and 
document the natural progression of disease. These subclinical measures are related to blood 
pressure waveforms and can be measured using a single, automated applanation tonometry 
device56. 
 Measures of arterial stiffness have been associated with traditional CVD risk factors21 
and future clinical events and mortality67, 68.  However, heritability studies suggest that there is 
also a genetic influence on these traits (H2r range: PP 0.13172 to 0.50169; PWV 0.19141 to 0.54142). 
Heritability studies of arterial stiffness measures have mostly been conducted in older, Caucasian 
adults 140, 141, 143, 164, 168, 169. However, hypertension prevalence is significantly greater in 
individuals of African descent compared to Caucasians1. Therefore, the genetic determinants of 
subclinical CVD traits related to hypertension are of particular importance in African ancestry 
populations who are at increased risk of CVD. In the current study, we examined the clinical 
correlates and heritability of arterial stiffness and blood pressure measures in seven large, 
multigenerational families of African ancestry from the Caribbean island of Tobago. In addition, 
we conducted genome-wide linkage using single nucleotide polymorphisms (SNPs) to identify 
quantitative trait loci for arterial stiffness in these African ancestry families. 
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4.3 MATERIALS AND METHODS 
4.3.1 Study Sample 
Participants for this analysis were from the Tobago Family Health Study. Briefly, 8 probands 
were originally recruited without regard to their medical history from a cohort study of bone 
mineral density and body composition on the Caribbean island of Tobago4. Probands were 
eligible if they had a spouse willing to participate and had at least six living offspring and/or 
siblings aged ≥18 years and who were residing in Tobago. All first-, second-, and third-degree 
relatives of the probands and their spouses were invited to participate. Since 2003, 471 
individuals belonging to 8 large families were recruited. Two families were later combined based 
on a discovered shared ancestry. The families consist of: 21, 26, 28, 49, 96, 98 and 153 
individuals (mean = 67 individuals) and 4,206 relative pairs. The sample consists of 283 women 
and 188 men aged 18-103 years (mean age, 43 years). 
 An ancillary study in 2007 invited all participants to have their PWV and blood pressure 
measured using an automated tonometry machine. There were 392 participants who returned 
(82% of participants) and completed a PWV assessment. For this analysis, we excluded 
individuals on hypertensive medication (n=31) leaving a final sample of 361 individuals (145 
males, 216 females). Written informed consent was obtained from each participant. The Tobago 
Division of Health and Social Services and the University of Pittsburgh Institutional Review 
Boards approved this study. 
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4.3.2 Arterial Stiffness and Blood Pressure Measurements 
Arterial stiffness related traits were measured using a non-invasive, waveform analyzer (Colin-
VP1000, Omron, Japan/WaveNexus, TX) as previously described75. Following 10 minutes of 
rest in a supine position, occlusion/monitoring cuffs are placed at standardized locations on the 
lightly clothed arm and bare ankle. Then, ECG electrodes are placed on the arm and ankle to 
visually monitor heart beat electric signals, while a phonocardiogram is placed on the left edge of 
the sternum to audibly detect heart sounds. The cuffs are connected to a plethysmographic sensor 
and an oscillometric pressure sensor, which record volume pressure waveforms and blood 
pressure, respectively. The volume pressure waveforms were collected at the arm (brachial 
artery) and ankle (tibial artery) over a total sampling time of 10 seconds with automatic gain 
analysis and quality adjustment. Blood pressures used for this study were means of the right and 
left side arteries and were measured by the oscillometric method using the above cuffs. Pulse 
pressure was calculated as systolic BP subtracted by diastolic BP.  
 Pulse-wave velocity was calculated as the (distance between arterial sites in cm) / (time 
between the foot of the waveforms in s). The distance is measured using a height based formula, 
rather than the physical distance on the outside of the participant, which was presented by 
Yamashina et. al. in 2002: path length from the heart to the brachium (Lb) =0.2195 x height of 
the patient (cm) - 2.0734; path length from the heart to ankle (La) = 0.8129 x height of the 
patient (cm) + 12.32856. This formula also accounts for the opposite direction of blood flow by 
subtracting the distance from the brachial artery to the heart. The actual baPWV, then, is 
calculated with: (La-Lb)/(time between brachial and ankle waveform). Mean baPWV was used 
in this analysis as the average between left and right baPWV measures.  
69 
4.3.3 Other Measures 
Cardiovascular risk factors available for this analysis included age, sex, weight/height or BMI, 
current smoking, alcohol intake, walking for exercise, diabetes, menopausal status, parity, oral 
contraceptive use, lipoprotein concentrations and heart rate. Additionally, systolic BP was tested 
for association with baPWV only. Body weight was measured to the nearest 0.1 kg on a balance 
beam scale. Standing height was measured to the nearest 0.1 cm, without shoes, using a wall-
mounted stadiometer. Waist circumference at the top of the hipbone was measured to the nearest 
0.1 cm. Body mass index was calculated as weight in kilograms divided by standing height in 
meters2.  
Demographic, lifestyle and medical history variables were collected by trained clinic staff 
through administration of a questionnaire and interview. Race was based on self-report of 
grandparental ethnic origin. The Tobago population is predominately of West African origin 
with low admixture6. Smoking status was classified as either current or not (yes/no), and 
participants reporting ever smoking <100 cigarettes in their lifetime were considered non-
smokers. Alcohol consumption was assessed by questionnaire and is coded based on having >1 
drink per week (yes/no) because there was a very low prevalence of substantial alcohol intake. 
Physical activity was “not active” or “active” determined by a median split (≤25 minutes 
walked/week vs. >25 minutes walked/week, respectively). Participants were asked to bring 
current medications to their interview, and staff recorded each medication. Diabetes was defined 
as a fasting glucose level ≥126 mg/dl or current use of diabetes medication. 
 Reproductive characteristics included menopausal status, parity, oral contraceptive (OC) 
use, and hormone replacement therapy (HRT). Because only 5/283 women reported using HRT, 
this variable was not included in this analysis. Women were considered postmenopausal only if 
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they had no menses for at least 12 months and were >40 years old, or if they had a hysterectomy 
or ovariectomy. 
4.3.4 Lipid Measurements 
A fasting blood sample was collected at the time of interview. Serum samples were separated 
and stored at -80°C until time of assay. Lipid measures (LDL-c, HDL-c and triglycerides) were 
assessed in the Heinz Nutrition Laboratory at the University of Pittsburgh’s Graduate School of 
Public Health, which has met the accuracy and precision standards of the Centers for Disease 
Control and Prevention and is CLIA certified. HLD-c was determined using the selective 
heparin/manganese chloride precipitation method. LDL-c was calculated by means of the 
Friedewald equation. Triglycerides were determined enzymatically using the procedure of 
Bucolo and David227. 
4.3.5 Genotyping and Multipoint Identity-By-Descent (IBD) Calculation 
Genomic DNA was isolated from whole blood extracted by the salting out method and isolated 
by a Qiagen column procedure (Qiagen, Santa Clara, CA). Whole-genome genotyping by 
fluorescence-based methods was performed using the Infinium HumanLinkage-12 Genotyping 
BeadChip (Illumina, San Diego, CA). After excluding singly nucleotide polymorphisms (SNPs) 
with call rate <90%, Hardy-Weinberg equilibrium (P<0.001), minor allele frequency <0.05 or 
multipoint IBD calculation incompatibility, we retained 1512 autosomal SNPs and used the 
Markov chain Monte Carlo algorithm as implemented in the program Loki228 to calculate 
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multipoint IBD. The final SNP set had a median MAF of 0.325 with a median spacing of 1.92 
cM based on the Kosambi mapping function229. 
4.3.6 Statistical Analysis 
All traits were assessed for non-normality and transformed as necessary. Outliers, defined as ≥4 
SD from the mean, were removed; no more than 2 observations were removed from any trait. To 
determine significant correlates of each measure, we tested covariates separately in an age and 
sex adjusted model. Age and sex were forced into all models because they are known correlates 
of subclinical CVD. Because we analyzed family data, we used the variance component 
framework as implemented in the program SOLAR112, which accounts for the non-independence 
between observations by using a familial correlation matrix. All potentially significant covariates 
(P<0.10) were then assessed simultaneously for each trait; we required a p-value <0.05 for 
inclusion in our final models.  
Maximum likelihood methods were used to simultaneously model the effect of additive 
genetics, or heritability (h2), fixed covariate effects and error. Heritability reported herein is the 
residual heritability (h2r), which is estimated as the proportion of phenotypic variation after the 
effects of covariates have been removed. 
To compare the effects of covariates across all traits, we calculated the percent difference 
in the ultrasound trait per unit increase in covariate. Percent differences were calculated as beta 
coefficient*unit/mean trait value*100. For continuous variables, the unit range was 1 SD, and for 
dichotomous variables, the unit range was 1.  
Multipoint linkage analysis was performed using an extension of the variance 
components model described above. Maximum likelihood methods were used to estimate the 
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expected variance attributable to a theoretical QTL, based on the expected covariance between 
relatives, which were estimated using the multipoint IBD probabilities. The model containing the 
parameter for the theoretical QTL was then compared with models incorporating only polygenic 
effects using a likelihood ratio test. Logarithm of the odds (LOD) scores, computed as the log10 
of the likelihood ratio, were used to assess the significance of the test. LOD score thresholds of 
3.3 and 2.0 were considered to represent nominal genome-wide significant and suggestive 
evidence for QTLs, respectively231. 
4.4 RESULTS 
4.4.1 Family Study Characteristics 
Characteristics of the family members are reported in Table 4.6.1. On average, individuals were 
41 years old (range 18-86 years). Women had significantly greater BMI than men; although the 
women weighed significantly less than the men, they were also significantly shorter (P<0.05 for 
all). Men were more likely to smoke and consume alcohol than women, although the prevalence 
of these activities was generally low. Diabetes prevalence was 8% and did not differ between 
men and women. Hypertension was significantly higher in men versus women (25.0% vs. 16.4%, 
P<0.05).  
 Blood pressure and arterial stiffness related measures are described in Table 4.6.1 and 
depicted in Figure 4.6.1. PP and baPWV measures were not suggestive of extensive arterial 
stiffness, especially in the younger age groups. Mean arterial stiffness measures were lower in 
women than in men (P<0.05). Pulse pressure increased with age and women had lower PP than 
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men at younger ages (age <50 years). However, PP was greater in women than men after age 50. 
Brachial-ankle PWV was similar in men and women across all ages. Both men and women 
appeared to have similar increases in baPWV across or 10-year age categories. Mean brachial 
SBP was 132.3 mmHg and mean brachial DBP was 76.1 mmHg. Women had lower blood 
pressure than men (P<0.05). 
4.4.2 Environmental Correlates of Arterial Stiffness and Blood Pressure 
Significant covariates for each trait are presented in Table 4.6.2. Age and sex were forced into all 
models; in addition, heart rate and BMI were significant predictors of most traits. For every 5-
year increase in age, blood pressure-related traits increased by 0.2-3.6% in this population 
(P<0.05 for all). Women had 6.4%-11.5% lower values of every trait than men (P<0.01 for all). 
Every 12.3 beats/min (1 standard deviation) greater heart rate was associated with 3.1-3.9% 
increased arterial stiffness or blood pressure measure (P<0.01 for all). Body-mass index was 
related to all blood pressure measures except baPWV. A 6.1 kg/m2 (1 standard deviation) greater 
BMI was associated with a 2.8-5.8% increased blood pressure measure (P<0.01 for all). 
 Pulse pressure was statistically significantly associated with menopausal status, such that 
post-menopausal women had 13.4% greater PP than pre-menopausal women and men (Figure 
1a; P<0.0001). Brachial-ankle PWV was also associated with height, SBP and diabetes. 
Increased height was associated with lower baPWV and both increased SBP and prevalent 
diabetes were each associated with a ~7% increase in baPWV. Covariates explained 26 to 66% 
of the variance in the arterial stiffness and blood pressure traits. 
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4.4.3 Variance Components and Linkage Analysis of Arterial Stiffness and Blood 
Pressure 
Genetic heritability estimates and results from genome-wide linkage analysis are presented in 
Table 4.6.3. After adjustment for covariates listed in Table 4.6.2, all traits had low, but 
significant, heritability ranging from 0.244 for baPWV to 0.399 for mean brachial DBP 
(P<0.05). Only one chromosomal region demonstrated suggestive evidence of linkage. The peak 
was located (maximum LOD=2.55) on chromosome 5 at 35 cM for PP. No other trait 
demonstrated suggestive evidence of linkage (LOD>2.0). 
4.5 DISCUSSION 
We conducted heritability and linkage analyses of blood pressure and arterial stiffness related 
measures in a homogenous, African ancestry pedigree sample. Blood pressure and arterial 
stiffness measures were significantly heritable with environmental factors accounting for a 
greater proportion of the variation in these traits. Nonetheless, our genome-wide analysis 
revealed suggestive evidence of linkage for pulse pressure on chromosome 5.   
There are 15 genes underlying the linkage region for pulse pressure peak (range: 
chromosome 5, 28-41 cM, 10.9-21.2Mbp). Several genes in this region have been related to 
cardiovascular disease including dynein axonemal heavy chain 5 (DNAH5), family with 
sequence similarity 134, member B (FAM134B), ankylosis progressive mouse homolog (ANKH) 
and myosin X (MYO10). Our findings are consistent with a genome-wide association study that 
found SNPs in DNAH5 to be associated with both ankle-brachial index, a measure of peripheral 
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arterial disease, and carotid IMT130. Others have found an interaction between alleles in 
FAM134B and TNFRSF19 to be associated with risk of vascular dementia269. SNPs in ANKH 
have been associated with vascular, calcification270, 271 and variants in MYO10 have been 
associated with BMP-related angiogenesis272. Collectively, these findings suggest that the 
chromosome 5 region may harbor potentially important candidate genes for vascular physiology. 
All measures of blood pressure and arterial stiffness increased with age. Previous 
population studies in mainly White participants, have reported that while SBP increases with 
age, DBP also decreases at later ages, resulting in increased PP273, 274. However, this was not 
observed in the present study. While PP did increase with age, it was not due to a decrease in 
DBP. Rather, DBP leveled off at older ages as SBP continued to rise, resulting in elevated PP in 
the oldest adults. We also found that women had significantly lower measures of blood pressure 
and arterial stiffness than men. This observation is consistent with reports in Whites79, 83, 274 and 
Blacks275. Also, PP increased in women after the menopausal transition, eventually exceeding 
values in men, which is consistent with previous reports274, 276. The mean PP was >50 mmHg in 
individuals under the age of 40 in this population (mean PP: men, 58.1 mmHg; women, 51.0 
mmHg), which is much higher than what is reported in populations of mostly White individuals, 
such as NHANES273 and the Framingham Heart Study274 with population-level pulse pressures 
under 40 mmHg in similarly aged individuals. Even in the Bogalusa Heart Study, which 
examined young (aged 20-38) Black and White individuals, the mean PP was 48 mmHg and 45 
mmHg for men and women, respectively275. Another study that examined brachial PP in African 
Americans also reported lower PP than values in our sample at younger ages (age 30-39 PP=45 
mmHg; age 40-49 PP=47 mmHg). However, among individuals over 60 years of age, PP was 
similar to values in our sample110. Therefore, this sample of Afro-Caribbean families has 
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markedly greater brachial PP under the age of 50 than has been seen in other populations, 
although measures in older adults are similar to other African American samples. 
To our knowledge, this is the first study to present values for baPWV separately for men 
and women by age group in African ancestry individuals. Most previous studies were conducted 
in Asian populations73, 74, 277. In our study, baPWV increased with age and was lower in females 
than males. Menopausal status was not significantly associated with baPWV. A significant 
relationship between menopause and baPWV has been reported previously73-75, 277. The lack of 
association in our study may be due to limited statistical power to detect a difference, or due to 
ethnic differences in disease etiology. Measures of baPWV were greater in this African ancestry 
sample than in a report of >12,000 Japanese74. This is consistent with other reports, which have 
suggested that PWV is greater in African ancestry populations than other ethnic groups across all 
ages29, 80, 82, 278, 279. While, at younger ages, the baPWV measures from our study (age < 30 years) 
are more similar to measures reported in Japanese280, they are much greater when compared to 
reports in older Japanese adults (age 60 years)281.  Therefore, it appears that this African ancestry 
sample may have increased baPWV and possibly more arterial stiffness as assessed by baPWV, 
than in other cohorts, especially over the age of 30, which is similar to our observations for PP. 
In addition to age and sex, heart rate and body size were both significant correlates of 
arterial stiffness. Body size was the strongest correlate of arterial stiffness measures consistent 
with previous findings of an adverse impact of adiposity on arterial stiffening21, 77, 106. However, 
other traditional factors associated with arterial stiffness measures, such as smoking21, 107, 109, 
diabetes21, 106, 107 and serum lipids21, 106, 107 were not consistent correlates in our sample. The 
prevalence of smoking was very low in our families and likely limited our ability to detect any 
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relationship.  Also, the impact of some risk factors on arterial stiffness may not have manifested 
yet in these relatively young and healthy families. 
Blood pressure and arterial stiffness measures were significantly heritable in these 
African ancestry families. However, heritability of the arterial stiffness traits was lower in our 
families (h2r < 0.3) compared to reports in other related individuals (h2r > 0.3 usually). The lower 
heritability estimate in these families may indicate that environmental factors are more important 
than genetics in this group.  
 This study examined arterial stiffness related phenotypes across a large age range in 
African ancestry families. Measures of blood pressure and arterial stiffness were consistently 
related to age, sex, body size and heart rate.  Values in our sample of families were more adverse 
than published values in other ethnic groups. We also found evidence for a low but statistically 
significant heritability of these traits, suggesting that genetic factors may not have a strong 
impact on blood pressure and arterial stiffness in these families. Although heritability was low, 
we found suggestive evidence of linkage to PP on chromosome 5. Further studies are needed to 
refine the potential association of the genes underlying this linkage peak to PP. 
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4.6 TABLES AND FIGURES 
Table 4.1 Characteristics* of the Afro-Caribbean Family Members 
Trait All (n=361) 
Men 
(n=145) 
Women 
(n=216) 
Age (years) 40.7 ± 15.6 41.5 ± 15.3 40.2 ± 15.7 
BMI (kg/m2) 28.0 ± 6.1 26.8 ± 5.1 28.9 ± 6.5‡ 
Weight (kg) 81.8 ± 18.6 84.1 ± 18.2 80.2 ± 18.8‡ 
Height (cm) 170.9 ± 8.2 177.1 ± 6.6 166.7 ± 6.2‡ 
Waist Circumference (cm) 88.5 ± 14.7 90.0 ± 12.8 87.5 ± 15.7 
Current Smoker (%) 4.8 11.3 0.5‡ 
>1 Drink per week (%) 41.2 58.3 29.8‡ 
≥25 Min walk per week (%) 70.3 72.9 65.8 
Diabetes (%) 7.6 6.7 8.2 
Hypertensive¥ (%) 19.9 25.0 16.4‡ 
Heart Rate (beats/min) 72.5 ± 12.3 68.6 ± 12.2 75.1 ± 11.7‡ 
LDL-c (mg/dl) 130.8 ± 40.0 127.6 ± 36.1 133.0 ± 42.3 
HDL-c (mg/dl) 40.0 ± 11.9 40.4 ± 11.1 39.8 ± 12.4 
Triglycerides (mg/dl) 86.2 ± 42.6 93.1 ± 50.4 81.7 ± 36.1‡ 
Menopausal (%)† 15.2 N/A 15.2 
Parity (%)† 44.6 N/A 44.6 
Oral Contraceptive (%)† 20.3 N/A 20.3 
Pulse Pressure (mmHg) 55.90 ± 10.90 57.42 ± 8.90 54.87 ± 11.97‡ 
Pulse-Wave Velocity (cm/s) 1368.44 ± 317.91 1416.59 ± 305.05 1335.41 ± 323.02‡ 
Mean Brachial SBP (mmHg) 132.32 ± 21.83 135.98 ± 19.23 129.86 ± 23.14‡ 
Mean Brachial DBP (mmHg) 76.05 ± 12.89 78.20 ± 12.08 74.62 ± 13.23‡ 
*Characteristics are shown as mean ± SD or frequency (%) 
¥Based on systolic blood pressure ≥ 140 and/or diastolic blood pressure ≥ 90, individuals taking 
antihypertensive medication are excluded in all analyses 
†Frequency in women only 
‡Comparison by sex is statistically significant (p<0.05) 
SBP: systolic blood pressure; DBP: diastolic blood pressure 
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Table 4.2 Significant Covariate Associations with Arterial Stiffness Indices 
Trait Age (5 yrs) 
Female 
Sex 
Heart Rate 
(12.3 bt/min) 
BMI 
(6.1 kg/m2)
Height 
(8.2 cm) 
SBP 
(12.8 mmHg) Menopause Diabetes 
Covariate 
Effects (r2) 
Pulse Pressure 0.9† -11.5§ 3.2‡ 5.8§   13.4§  0.028 
Pulse-Wave Velocity 3.6§ -7.2‡ 3.8§  -2.5‡ 7.4§  6.7† 0.662 
Mean Brachial SBP 0.2§ -6.7§ 3.1§ 4.0§     0.303 
Mean Brachial DBP 2.3§ -6.4§ 3.9§ 2.8‡     0.323 
Values shown by covariate depict the percent change in trait value for each unit change in covariate value. Unit values are 1 for 
dichotomous values and are shown in parentheses for continuous values.  
SBP: systolic blood pressure; DBP: diastolic blood pressure 
†P<0.05 
‡P<0.01 
§P<0.0001 
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Table 4.3 Heritability and Results of Linkage Analysis of Arterial Stiffness Indices 
Trait* Genetic Effects (h2r ± SE) 
Max 
LOD Chromosome cM (range)
§ 
Pulse Pressure 0.269 ± 0.124† 2.545 5 35 (28-41) 
Pulse-Wave Velocity 0.244 ± 0.147† 1.873 13 23 (13-33) 
Mean Brachial SBP 0.285 ± 0.103‡ 1.628 16 95 (91-102) 
Mean Brachial DBP 0.399 ± 0.103‡ 1.400 2 272 (265-qTer) 
*All analyses were adjusted for covariates listed in Table 4.6.2 above 
§Location defined by the position of the peak LOD±1.0 
PWV: brachial-ankle pulse-wave velocity; SBP: systolic blood pressure; DBP: diastolic blood 
pressure 
†P<0.05 
‡P<0.001 
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Figure 4.1 Arterial Stiffness and Blood Pressure Traits by Sex and 10-year Age Group 
Mean and standard errors or prevalence of pulse pressure (a), brachial-ankle pulse-wave velocity 
(b), brachial systolic blood pressure (c) and brachial diastolic blood pressure (d) are plotted by 
10-year age group for men (grey) and women (black), separately. PP: pulse pressure; PWV: 
brachial-ankle pulse-wave velocity; SBP: systolic blood pressure; DBP: diastolic blood pressure 
82 
5.0  MANUSCRIPT 3: GENETIC CORRELATION AND GENOME-WIDE LINKAGE 
ANALYSIS OF SUBCLINICAL CARDIOVASCULAR DISEASE AND INDICES OF 
OSTEOPOROSIS 
Allison L Kuipers, BS1, Candace M Kammerer, PhD2, Genevieve Woodard, PhD1, Iva 
Miljkovic, MD, PhD1, Amy S Dressen, MS2, Hu Li, PhD, MS1, Clareann H Bunker, PhD1, Alan 
L Patrick, FRCP3, Victor W Wheeler, MBBS, MRCOG3, Anne B Newman, MD, MPH1, Kim 
Sutton-Tyrrell, DrPH1, Joseph M Zmuda, PhD1,2 
 
1Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA 
2Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA 
3Tobago Health Studies Office, Scarborough, Tobago, Trinidad and Tobago 
 
Manuscript in preparation. 
83 
5.1 ABSTRACT 
Both cardiovascular disease (CVD) and osteoporosis (OP) risk and prevalence increase with age. 
Subclinical measures of these diseases have been correlated such that adverse vascular health 
indices are associated with lower bone mineral density (BMD). In the current study, we 
estimated the phenotypic and genetic correlation between subclinical CVD measures and BMD. 
We also performed bivariate genome-wide linkage analysis of these traits. A total of 461 African 
ancestry individuals belonging to 7 large, multigenerational families were recruited without 
regard to health status (mean family size 66; 3,414 relative pairs). Participants underwent carotid 
ultrasound scans to determine adventitial diameter (AD) and intima-media thickness (IMT). 
Dual-energy X-ray absorptiometry and peripheral quantitative computed tomography were used 
to determine BMD. We determined genetic correlation and conducted bivariate, multipoint 
quantitative trait linkage analyses using pedigree-based maximum likelihood methods on models 
adjusted for age, sex, weight, height, menopausal status, current smoking, alcohol intake and 
walking for exercise. Significant evidence for genetic correlation was identified between AD and 
BMD (rhoG range -0.043 to -0.059; P<0.05). IMT was significantly genetically correlated with 
integral BMD in the lumbar spine (rhoG=-0.35, P<0.05) and borderline significantly correlated 
with trabecular BMD in the radius (rhoG=-0.33; P<0.10). Bivariate linkage analysis identified a 
region on chromosome 14 that may harbor genes with pleiotropic effects on AD and BMD (max 
LOD=5.2, 61 cM). This peak contains candidate genes, such as BMP4 and ESR2, but needs to be 
refined to determine which genes may have pleiotropic effects on CVD and OP. 
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5.2 INTRODUCTION 
Bone mineral density (BMD) has been inversely associated with subclinical and clinical CVD, 
even after adjusting for potential confounding factors182, 183, 212-214. However, the underlying 
physiologic link between these two disease processes is not completely understood. For the most 
part, the correlation between BMD and CVD has been observed in purely epidemiologic or 
experimental studies, and the potential for pleiotropic genetic effects have not been investigated. 
 Epidemiologic studies have mainly focused on investigating the correlation of arterial 
calcification and calcified plaque with bone mineral density (BMD) and fractures in various 
populations including individuals with CKD and post-menopausal women, in addition to, the 
general population of various ethnic groups including Whites, Mexican Americans and 
Japanese183-188. However, this relationship has not been adequately investigated in populations of 
African ancestry, even though there is a lower risk of OP and higher risk of any CVD event than 
in Caucasians. Subclinical atherosclerosis, as assessed by IMT, has been associated with low 
BMD, mainly at the lumbar spine and hip191, 193, 198, 206. To our knowledge, no studies have 
examined the correlation of other carotid ultrasound characteristics with BMD. Therefore, we 
assessed the heritability, phenotypic and genetic correlations between subclinical CVD, assessed 
by carotid ultrasound, and BMD in Afro-Caribbean families in Tobago. We also used bivariate, 
genome-wide linkage analysis to identify genomic regions that may have pleiotropic effects 
resulting in the coupling of CVD and bone phenotypes. 
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5.3 MATERIALS AND METHODS 
5.3.1 Study Sample 
Participants for this analysis were from the Tobago Family Health Study. Briefly, 8 probands 
were originally recruited without regard to their medical history from a cohort study of bone 
mineral density and body composition on the Caribbean island of Tobago4. Probands were 
eligible if they had a spouse willing to participate and had at least six living offspring and/or 
siblings aged ≥18 years and who were residing in Tobago. All first-, second-, and third-degree 
relatives of the probands and their spouses were invited to participate. In 2003-2004, we 
recruited 471 individuals belonging to 8 large families. Two families were later combined based 
on a discovered shared ancestry. The families consist of: 21, 26, 28, 49, 96, 98 and 153 
individuals (mean = 67 individuals) and 4,206 relative pairs. The sample consists of 283 women 
and 188 men aged 18-103 years (mean age, 43 years). 
 An ancillary study in 2007 invited all family members to complete carotid ultrasound 
imaging. There were 415 participants who returned (88% of survivors) and completed the carotid 
scan, 395 of whom had useable data. In addition, bone mineral density was screened in 445 
individuals at the initial baseline visit. We have analyzed the data from 461 individuals (184 men 
and 277 women) with ultrasound and/or BMD assessment, who form the basis of these analyses. 
Written informed consent was obtained from each participant. The Tobago Division of Health 
and Social Services and the University of Pittsburgh Institutional Review Boards approved this 
study. 
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5.3.2 Subclinical Cardiovascular Disease Traits 
The common carotid artery was imaged with B-mode ultrasonography using an Acuson Cypress 
portable ultrasound machine (Siemens Medical Solutions, Malvern, PA). Both the near and far 
walls of the distal common carotid artery were captured for one centimeter proximal to the 
carotid bulb. Only the common carotid artery could be imaged with the portable technology. 
Intima-media thickness (IMT) was obtained using a semi-automated reading software system 
(AMS system; Dr. Thomas Gustavsson, Sweden). This system detects and traces lines, with 
reader input, between the lumen-intima and media-adventia borders across the 1 cm segment. 
Then, the software generates one thickness measurement per pixel across this area, for about 140 
measures in total. Mean IMT measures correspond to the mean IMT across all pixels of both the 
near and far wall of the common carotid artery on both the right and left arteries. Adventitial 
diameter measures were obtained from the same 1 cm region and correspond to the distance 
between near and far wall medial-adventitial borders. Both sides of each participant were 
averaged to obtain the mean AD. All images were read centrally at the Department of 
Epidemiology’s Ultrasound Research Laboratory (University of Pittsburgh, Pittsburgh, PA). 
Reproducibility analyses were conducted on 35 Tobago Family Health Study participants. The 
inter-sonographer intraclass correlation (ICC) was 0.97 for mean IMT and 0.95 for mean AD. 
Inter-reader ICC was 0.99 for mean IMT and mean AD. 
5.3.3 Bone Mineral Density Measures 
Measures of integral areal BMD at the spine and proximal femur were measured by dual energy 
X-ray absorptiometry (DXA) using a Hologic QDR-4500W densitometer (Hologic Inc., Bedford, 
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MA). Trabecular and cortical volumetric BMD at the non-dominant forearm and left tibia was 
measured by peripheral quantitative computed tomography (pQCT) using an XCT-2000 scanner 
(Stratec Medizintechnik, Pforzheim, Germany). Technicians followed standardized protocols for 
patient positioning and scanning. A scout view was obtained prior to the pQCT scan to define an 
anatomic reference line for the relative location of the subsequent scans (4% and 33% of the total 
length) at the radius and tibia. Tibia length was measured from the medial malleolus to the 
medial condyle of the tibia, and forearm length was measured from the olecranon to the ulna 
styloid process. A single axial slice of 2.5 mm thickness with a voxel size of 0.5 mm and a speed 
of 20 mm/s was taken at all locations. Image processing was performed using the Stratec 
software package (Version 5.5E). The short-term in vivo precision of the pQCT measurements 
for 15 subjects ranged from 0.65% (tibia cortical BMD) to 2.1% (tibial trabecular BMD). 
5.3.4 Other Measurements 
Covariates available for this analysis included age, sex, height, weight, current smoking, alcohol 
intake, walking for exercise, diabetes, hypertension, menopausal status, parity and lipoprotein 
concentrations. Body weight was measured to the nearest 0.1 kg on a balance beam scale. 
Standing height was measured to the nearest 0.1 cm, without shoes, using a wall-mounted 
stadiometer.  
 Demographic, lifestyle and medical history variables were collected by trained clinic staff 
through administration of a questionnaire and interview. Race was self-reported based on 
grandparental ethnic origin. The Tobago population is predominately of West African origin 
with low admixture6. Smoking status was classified as either current or not (yes/no), and 
participants reporting ever smoking <100 cigarettes in their lifetime were considered non-
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smokers. Alcohol consumption was assessed by questionnaire and was coded based on having 
>1 drink per week (yes/no) because there was a very low prevalence of substantial alcohol 
intake. Physical activity was assessed by the number of minutes walked per week and 
participants were dichotomized into “not active” or “active” determined by a median split (≤25 
minutes walked/week vs. >25 minutes walked/week, respectively). Participants were asked to 
bring current medications to their interview, and staff recorded each medication. Diabetes was 
defined as a fasting glucose level ≥126 mg/dl or current use of diabetes medication. 
Hypertension was defined as a seated diastolic blood pressure ≥90 mmHg, systolic pressure ≥140 
mmHg and/or current use of anti-hypertensive medication. 
5.3.5 Genotyping and Multipoint Identity-By-Descent (IBD) Calculation 
Genomic DNA was isolated from whole blood extracted by the salting out method and isolated 
by a Qiagen column procedure (Qiagen, Santa Clara, CA). Whole-genome genotyping by 
fluorescence-based methods was performed using the Infinium HumanLinkage-12 Genotyping 
BeadChip (Illumina, San Diego, CA). The BeadChip included 6,090 single-nucleotide 
polymorphism (SNP) markers with an average spacing of 0.58 cM across the genome. After 
excluding SNPs with call rate <90%, Hardy-Weinberg equilibrium (P<0.001), minor allele 
frequency <0.05, we retained 5361 autosomal SNPs. From these SNPs, we selected a subset of 
1512 SNPs, with a correlation <0.30 and ≥ 1 cM apart for multipoint IBD calculation because the 
Markov chain Monte Carlo algorithm as implemented in the program Loki228 requires markers to 
be ≥1cm apart. For markers located at the same cM position on a chromosome, we selected the 
SNP that had the highest MAF. The final SNP set had a median MAF of 0.325 with a median 
spacing of 1.92 cM based on the Kosambi mapping function229. 
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5.3.6 Statistical Analysis 
All traits were assessed for non-normality and transformed as necessary. Outliers, defined as ≥4 
SD from the mean, were removed for each trait; no more than 2 observations were removed from 
any trait. We adjusted each heritability, correlation and linkage model for age, sex, body weight, 
height, menopausal status, walking for exercise, current smoking and alcohol intake. We did not 
include adjustment for other conditions that have been suggested to be part of the physiologic 
mechanisms underlying the correlation between cardiovascular and bone related measures such 
as diabetes212, hypertension196 and dyslipidemia223, 282. We used SOLAR112 to estimate the 
residual heritability and the variance attributable to the fixed covariate effects for each trait. 
SOLAR was also used to determine the extent of genetic and environmental correlation 
between the variance components of CVD and BMD measures112, 283. When two traits have 
significant genetic correlation (ρG), then there is evidence that they are partially controlled by the 
same genetic variation. When two traits have significant environmental correlation (ρE), then 
there is evidence that they are partially controlled by the same environmental factors. Phenotypic 
correlation (ρ) between CVD and BMD measures was estimated from heritability, genetic 
correlation and environmental correlation estimates as: ρ12 = ρG(√h21)(√h22) + ρE(1-√h21)(1-√h22). 
Pearson correlation coefficients were also estimated. The significance of the genetic correlation 
being different from zero or 1 (or -1) was then tested with a likelihood ratio test of the 
constrained and unconstrained models. Because the individual observations were not 
independent, we used variance component modeling.  
Quantitative trait linkage analysis was used to identify genomic regions that were 
inherited with each of the traits. The significance of the theoretical QTL was tested with a 
likelihood ratio test at 1 cM intervals across each autosomal chromosome. Maximum likelihood 
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methods tested whether the model containing a parameter for the theoretical QTL was more 
likely than the model incorporating only polygenic effects. Logarithm of the odds (LOD) scores, 
computed as the log10 of the likelihood ratio, were used to assess the significance of the test. 
LOD score thresholds of 3.3 and 2.0 were considered to represent nominal genome-wide 
significant and suggestive evidence for QTLs, respectively231. Computational power used to be a 
hindrance to the feasibility of these analyses for some pedigrees; however, using SOLAR112, 232 
this is now possible in extended pedigrees such as those in the Tobago Family Health Study, and 
is robust to type 1 error and has more power than traditional nuclear family linkage analyses233, 
234. 
For CVD and BMD trait-pairs with evidence of genetic correlation (P<0.1), we 
performed bivariate, whole-genome quantitative trait linkage analysis in order to identify 
genomic regions with potentially pleiotropic effects283 with the same methods as were used in 
univariate analyses. However, intrinsic to bivariate linkage methodology, the likelihood ratio 
tests had 2 degrees of freedom rather than the 1 in univariate analyses. Therefore, the LOD 
scores between univariate and bivariate analyses are not directly comparable; a LOD of 3.0 in 
univariate analysis is closer to a LOD of 3.5 from bivariate analyses283. 
5.4 RESULTS 
5.4.1 Family Study Characteristics 
Participant characteristics are shown in Table 5.6.1. The family members ranged in age from 18 
to 86 years (mean = 42.7 years). The sample was 60.1% female and 18.8% were post-
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menopausal. Men and women were similar in body weight (mean = 82.3 kg), but men were taller 
than women resulting in women having a greater BMI than men. Smoking and drinking at least 
one alcoholic drink per week were significantly more common in men than women (11.6% 
versus 0.4% and 61.8% versus 29.0%, respectively). The frequency of walking for exercise was 
similar in men and women (mean 70.8%). Diabetes was present in 9% and hypertension was 
present in 28.0% of the sample. There was no difference in diabetes or hypertension by sex. 
5.4.2 Variance Components of Univariate CVD and BMD Related Traits 
All cardiovascular and BMD related traits were determined to be heritable after adjusting for 
age, sex, menopause, body weight, height, smoking, alcohol intake and physical activity (Table 
5.6.2). Adventitial diameter had a residual heritability of 0.53 and IMT had a residual heritability 
of 0.44 (P<0.001 for both). Residual heritabilities of BMD at the femoral neck and lumbar spine 
were 0.54 and 0.59 (P<0.001 for both). Cortical BMD at the radius and tibia had the lowest 
residual heritabilities of any BMD trait (0.28 and 0.39, respectively; P<0.001 for both). In 
contrast, trabecular BMD had the greatest residual heritability (0.71 and 0.67 at the radius and 
tibia, respectively; P<0.001 for both). Covariates explained between 18% and 55% of the 
variance in cardiovascular and BMD related traits. 
5.4.3 Univariate Linkage of CVD and BMD Related Traits 
We initially performed univariate whole-genome linkage analysis of the CVD and BMD related 
phenotypes  (data not shown; see Appendix: Table 7.1 and Figures 7.1 and 7.2). Analyses were 
adjusted for age, sex, menopause, body weight, height, smoking, alcohol intake and physical 
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activity. We identified significant linkage peaks for AD on chromosome 14 (max LOD = 4.71, 
54 cM) and for radial trabecular BMD on chromosome 11 (max LOD = 3.44, 24 cM). A 
suggestive linkage peak was identified for IMT on chromosome 13 (max LOD = 2.36, 114 cM). 
Lumbar spine BMD also had a peak suggestive of linkage on chromosome 1 (max LOD = 2.53, 
104 cM). Suggestive linkage peaks identified for cortical BMD differed by anatomical site. At 
the radius, a suggestive peak was identified on chromosome 12 (max LOD = 2.28, 80 cM) 
whereas at the tibia suggestive linkage peaks were identified on chromosomes 2 (max LOD = 
2.62, 73 cM) and 19 (max LOD = 2.81, 42 cM). Despite significant heritabilities, there were no 
linkage peaks identified for femoral neck BMD or tibial trabecular BMD. 
5.4.4 Correlation of CVD and BMD Related Traits 
Correlations between CVD and BMD related traits are reported in Table 5.6.3. Overall, we found 
that with an increase in AD, BMD traits decreased significantly. AD was negatively correlated 
with all BMD traits, with phenotypic correlation coefficients around -0.2 (P<0.05). Only the 
correlation between AD and trabecular BMD at the tibia was not significant (P>0.05), even 
though the magnitude was similar to other trait-pairs. There was also significant genetic 
correlation between AD and all BMD traits except cortical BMD at the radius. Genetic 
correlation coefficients were generally high and ranged from -0.43 to -0.59 (P<0.05 for all). 
There was no significant phenotypic correlation between IMT and any of the BMD measures. 
However, there was evidence of some inverse genetic correlation between IMT and lumbar spine 
BMD and trabecular BMD at the radius (ρG = -0.35 and -0.33; P<0.05 and <0.1, respectively). 
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5.4.5 Bivariate Linkage of CVD and BMD Related Traits 
We next performed bivariate, genome-wide linkage analysis for all CVD and BMD trait-pairs 
that had evidence of a genetic correlation (P<0.1) (Table 5.6.4 and Figures 5.6.1 and 5.6.2). We 
identified significant or suggestive bivariate linkage peaks for AD and BMD trait-pairs on 
chromosome 14 around 60 cM. The maximum LOD score was seen for AD and cortical BMD at 
the tibia (max LOD = 5.2). Other significant peaks were identified at the same region for femoral 
neck BMD, lumbar spine BMD and trabecular BMD at the radius and tibia (max LOD = 4.22, 
3.55, 3.69 and 4.16, respectively). Additionally, we identified a peak suggestive of linkage on 
chromosome 11 around 24 cM for both AD and IMT with trabecular BMD at the radius (max 
LOD = 2.86 and 3.14, respectively). There was no suggestive linkage peak identified for the IMT 
and lumbar spine BMD trait-pair. 
5.5 DISCUSSION 
We examined the heritability and bivariate linkage of subclinical measures of CVD and BMD in 
large, multigenerational families of African ancestry. The individuals in these African ancestry 
families had generally healthy arteries and high BMD even though they tended to be overweight 
and had a high prevalence of hypertension. Measures of subclinical CVD and BMD were highly 
heritable, as has been reported previously in these families (Section 3.0 and Wang et. al.284). We 
found a significant, inverse phenotypic and genetic correlation between AD and measures of 
BMD, particularly for trabecular BMD. Bivariate genome-wide linkage analysis revealed 
evidence of linkage on chromosomes 14 for AD and cortical BMD at the tibia with a maximum 
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LOD of 5.2. To our knowledge, this is the first evidence to suggest that there may be a genetic 
basis for the link between indices of vascular and bone health. 
The inverse phenotypic correlations suggest that persons with greater BMD (e.g., 
stronger bones) have smaller vessel diameters (e.g., healthier vasculature). This finding is 
consistent with previous reports of an association between vascular and bone health, in largely 
Caucasian ancestry populations. However, this is the first study to report a relationship with AD; 
the majority of previous reports have focused on arterial calcification as the marker of subclinical 
CVD183-188. In this cohort, IMT was not phenotypically correlated with BMD, in contrast to 
previous reports191, 193, 198, 206. The coefficients of correlation were negative for the most part; 
however, the magnitude of effect was small. This is likely due to the young and relatively 
healthy population that had very little atherosclerosis and, thus, had little variation in IMT 
measures. 
There was also a significant, inverse genetic correlation between AD and BMD related 
traits. This observation suggests that there are genes that may cause an increase in AD and 
decrease in BMD, and/or vice versa. The strongest genetic correlations to AD were observed for 
trabecular BMD and lumbar spine, a mainly trabecular bone site, BMD. This observation may 
reflect the fact that trabecular BMD had the greatest heritability in these families. We also 
identified significant genetic correlation between IMT and lumbar spine BMD and trabecular 
BMD at the radius, but not for any of the cortical bone measures. A stronger genetic correlation 
between IMT and trabecular compared with cortical bone has not been demonstrated before. 
Bivariate genome-wide linkage analysis revealed two linkage peaks with significant or 
suggestive evidence of linkage on chromosomes 11 and 14. The strongest evidence of linkage 
was identified on chromosome 14 for AD and cortical BMD at the tibia with a maximum LOD 
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of 5.2 at 61 cM. This linkage peak was originally seen in the univariate AD analyses, with a max 
LOD of 4.7 at 54 cM. Therefore, this peak in bivariate analyses is not a novel, genomic signal for 
AD and BMD, rather it is driven by the linkage with AD. Nonetheless, it is still of importance 
because it shows this region may have an impact on not only AD, but also on the etiology of the 
correlation of AD and BMD traits. The bivariate approach allowed identification of the 
importance of this region to the CVD-BMD relationship in these families, which is an advantage 
of the bivariate approach283.  
There are 153 known genes under the linkage peak on chromosome 14; yet, there are few 
that have been implicated in CVD and/or BMD regulation. The two strongest candidate genes 
are bone morphogenetic protein 4 (BMP4) and estrogen receptor 2 (ESR2). BMP4 was first 
identified as an important inducer of bone formation285. However, it has also been shown to be 
partly responsible for the differentiation of vascular smooth muscle cells (VCMCs) into bone-
forming, osteoblast-like cells260, 286, 287.  Activation of BMP4 by RANKL in the adventitia of the 
vessel wall induces the VCMCs to differentiate into non-contractile cells with bone forming 
capacity287, suggesting that there may be a role of BMP4 in regulating vascular calcification. 
Additionally, BMP4 may be involved in the vascular endothelial response to blood shear stress261 
and may also have a role in the inflammatory response of the arterial wall to lipids288. Therefore, 
BMP4 may be a strong candidate gene for both AD size and BMD regulation. However, there 
was no significant association between SNPs in BMP4 and vascular calcification in the only 
previous report to examine this association289. 
The ESR2 gene controls the genomic response to estrogens, which are strongly associated 
with atherosclerosis262 and BMD. Previously, genetic variation in this gene has been associated 
with subclinical CVD including IMT262 and PWV153. Estrogen is also related to BMD, and 
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variation in ESR2 has been associated with BMD290, fractures291 and osteoporosis292. ESR2 
genotypes may also aid in the prediction of clinical vascular disease risk beyond traditional risk 
factors293. There have been many in vitro studies of vascular calcification that show estrogens 
have a major role in its pathogenesis through regulation of cytokine and BMP activities182, 216, 220, 
294.  
However, there are other genes in this chromosomal region that could be responsible for 
the bivariate linkage signal including protein kinase C, eta (PRKCH) and hypoxia inducible 
factor 1 α (HIF1A). Variants in PRKCH have been associated with multiple bone traits in a 
recent GWAS295 and have also been associated with brain infarcts296, suggesting it may play a 
role in both CVD and osteoporosis. In vitro studies have shown that HIF1a is involved in both 
bone regeneration297 and angiogenesis298. In addition, there are numerous genes under the peak 
that have only been reported to be related to either CVD or OP, including SLC8A3, a known 
regulator of osteoblast function in bone299, 300; LGALS3, which may partly control serum 
lipids264; and GCH1, which is involved in oxidative stress265. 
Two previous genome-wide studies of arterial stiffness263 and subclinical CVD130 have 
identified this region on chromosome 14. The first study identified a suggestive linkage peak for 
PP/stroke-volume ratio in African Americans siblings, which overlaps with our peak263. Also, a 
genome-wide association study for coronary artery calcification in the Framingham Heart Study 
identified a significant association with a SNP in the drosophila NUMB homolog (NUMB) gene 
that resides at 72.8 MB within our identified genomic region on chromosome 14130.  
The other linkage peak identified in our bivariate analyses had suggestive evidence of 
bivariate linkage with a maximum LOD score of 3.14 on chromosome 11 at 24 cM for IMT and 
trabecular BMD at the radius. There was also suggestive evidence for linkage in this same region 
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for AD and trabecular BMD at the radius. Similar to the linkage peak on chromosome 14, this 
peak was also identified in the univariate linkage analysis, but for trabecular BMD at the radius. 
This suggests that this signal may not be a novel region with solely pleiotropic effects as the 
signal is driven by the linkage to BMD, but its reinforces its potential underlying genetic 
determination of variance in both traits or their correlation. 
There are 93 genes within this linkage region with many potential candidates for 
osteoporosis, CVD or osteoporosis and CVD traits. The most plausible genes with impacts on 
both OP and CVD traits include adrenomedullin (ADM) and its related genes, calcitonin-related 
polypeptide α and β (CALCA/B), parathyroid hormone (PTH) and sex-determining region Y-box 
6 (SOX6). Adrenomedullin is closely associated with calcitonin and the CALCA/B genes and is 
associated, in vitro, with osteoblast development301, inflammation302, 303 and vascular 
calcification304-307. Through epidemiologic studies, it has also been shown to be associated with 
diabetes308, vascular calcification309 and the correlation of adipose tissue with menopause310. 
Parathyroid hormone has a strong impact on bone metabolism311, but it has also been shown to 
enhance expression of atherosclerotic factors312. Similarly, SOX6 variants have been consistently 
related to BMD 313, 314 and with atherosclerotic plaques315. 
 In conclusion, we have identified strong, inverse phenotypic correlations between AD 
and measures of BMD in large, multigenerational African ancestry families that appear to have a 
genetic, rather than environmental, basis. We have also identified genetic, but not phenotypic, 
correlation between measures of IMT and trabecular BMD. Bivariate genome-wide linkage 
analysis with a high-density SNP panel identified two genomic regions with potential 
pleiotropic, not co-incident, effects on these CVD and BMD related traits. This is the first study, 
to our knowledge, to document a correlation of AD with BMD and the first to test for genetic 
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correlation and bivariate linkage between these measures of subclinical CVD and osteoporosis. 
Our findings further support the hypothesis that there is an underlying shared etiology of CVD 
and osteoporosis. Further refinement of our linkage peaks may reveal genes that underlie this 
link. 
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5.6 TABLES AND FIGURES 
Table 5.1 Characteristics of the Afro-Caribbean Family Members 
Trait All (n=461) 
Men 
(n=184) 
Women 
(n=277) 
Age (years) 42.74 ± 16.6 42.93 ± 17.0 42.62 ± 16.4 
Female Sex (%) 60.1 -- -- 
Post-menopausal (%)† 18.8 -- 18.8 
Weight (kg) 82.31 ± 18.4 84.03 ± 17.3 81.16 ± 19.0 
Height (cm) 170.73 ± 8.6$ 177.40 ± 7.1 166.32 ± 6.4 
Body Mass Index (kg/m2) 28.31 ± 6.3$ 26.68 ± 4.9 29.38 ± 6.9 
Current Smoker (%) 4.8$ 11.6 0.4 
>1 Drink per Week (%) 42.1$ 61.8 29.0 
Diabetes (%) 9.1 6.9 10.5 
Hypertension (%) 28.0 30.1 26.6 
* Characteristics are shown as mean ± SD or frequency (%) 
† Frequency in women only 
$ Difference by sex significant (P<0.05) 
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Table 5.2 CVD and BMD Related Traits in Afro-Caribbean Families 
Trait Mean ± SD* Genetic Effect (h2r ± SE)¥ 
Covariate Effects 
(r2) 
Mean AD (mm) 7.24 ± 0.7 0.530 ± 0.12 0.260 
Mean IMT (mm) 0.69 ± 0.1 0.443 ± 0.11 0.551 
Femoral Neck BMD (g/cm2) 0.99 ± 0.2 0.542 ± 0.10 0.331 
Lumbar Spine BMD (g/cm2) 1.09 ± 0.2 0.590 ± 0.09 0.206 
Radial Cortical BMD (g/cm3) 1217.12 ± 27.5 0.278 ± 0.09 0.222 
Tibial Cortical BMD (g/cm3) 1183.30 ± 31.0 0.393 ± 0.10 0.178 
Radial Trabecular BMD (g/cm3) 221.59 ± 42.6 0.706 ± 0.10 0.275 
Tibial Trabecular BMD (g/cm3) 248.77 ± 35.8 0.674 ± 0.10 0.303 
* Unadjusted mean and SD.  
Genetic effect estimates are adjusted for age, sex, weight, height, menopausal status, current 
smoking, alcohol intake and walking for exercise 
¥ All residual heritability estimates had a corresponding P<0.001 
IMT: intima-media thickness; AD: adventitial diameter; BMD: bone mineral density 
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Table 5.3 Correlation* Between CVD and BMD Related Traits 
Adventitial Diameter Intima-media Thickness Trait 
ρG ρE ρp r ρG ρE ρp r 
Femoral Neck BMD -0.502 0.164 -0.248 -0.183 -0.232 0.082 -0.103 -0.078 
Lumbar Spine BMD -0.589 0.288 -0.314 -0.197 -0.354 0.242 -0.156 -0.051 
Radial Cortical BMD -0.241 -0.246 -0.125 -0.223 0.095 -0.053 0.027 -0.002 
Tibial Cortical BMD  -0.429 -0.005 -0.202 -0.197 0.079 -0.019 0.029 0.002 
Radial Trabecular BMD  -0.537 0.204 -0.329 -0.215 -0.328 0.195 -0.167 -0.081 
Tibial Trabecular BMD  -0.517 0.370 -0.292 -0.130 -0.204 0.150 -0.098 -0.026 
*All correlation analyses adjusted for covariates listed in Table 5.6.3 
BMD: bone mineral density; ρG: genetic correlation; ρE: environmental correlation; ρP: 
phenotypic correlation (calculated); r: Pearson’s correlation coefficient (estimated) 
BOLD indicates coefficient is significant (P<0.05); ρP and r significance assessed by same 
variance components model outlined in methods section 
UNDERLINE indicates ρG is suggestive (P<0.10) and will be included in bivariate linkage 
analysis along with all significant ρG trait-pairs 
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Table 5.4 Bivariate, Genome-Wide Linkage Results for CVD-BMD Traits 
QTL Location Genes in Region CVD 
Trait 
BMD 
Trait 
Max 
LOD* Chr cM (range)§ 
Genomic 
(MBp) Cytogenetic N 
Potential 
Candidates 
AD FN 4.22 14 61 (51-70) 53.8-73.6 q22.2-24.3 116 BMP4; ESR2 
AD LS 3.55 14 54 (46-70) 49.5-73.6 q22.1-24.3 153 BMP4; ESR2 
AD TCort 5.20 14 61 (51-66) 53.8-70.2 q22.2-24.2 97 BMP4; ESR2 
AD RTrab 2.86 11 23 (20-34) 8.0-18.7 p15.4-15.1 93 ADM; SOX6; PTH 
AD RTrab 3.69 14 54 (45-70) 48.6-73.6 q22.1-24.3 153 BMP4; ESR2 
IMT RTrab 3.14 11 24 (20-38) 8.0-20.0 p15.4-15.1 86 ADM; SOX6; PTH 
AD TTrab 4.16 14 54 (45-68) 48.6-72.0 q22.1-24.2 146 BMP4; ESR2 
Only regions with a peak LOD ≥ 2.5 in bivariate analyses are shown 
* Analyses were adjusted for all covariates listed in Table 5.6.3 
§ Range defined by the position of the peak LOD±1.0 where peak LOD<3.5 and defined as 
LOD±2.0 where peak LOD≥3.5 
AD: adventitial diameter; IMT: intima media thickness; FN: femoral neck; LS: lumbar spine; 
TCort: tibia cortical; RTrab: radius trabecular; TTrab: tibia trabecular 
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Figure 5.1 Bivariate, Genome-Wide Linkage Results for Adventitial Diameter and BMD Related 
Traits 
LOD scores from bivariate, genome-wide linkage analysis of adventitial diameter and BMD trait 
pairs with significant genetic correlation are plotted by chromosome for each trait. Horizontal 
lines are drawn at LOD=2.5 and 3.5 to signify thresholds for suggestive and significant bivariate 
linkage, respectively. BMD: bone mineral density 
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Figure 5.2 Bivariate, Genome-Wide Linkage Results of Intima-Media Thickness and BMD Related 
Traits 
LOD scores from bivariate, genome-wide linkage analysis of intima-media thickness and BMD 
trait pairs with significant genetic correlation are plotted by chromosome for each trait. 
Horizontal lines are drawn at LOD=2.5 and 3.5 to signify thresholds for suggestive and 
significant bivariate linkage, respectively. BMD: bone mineral density 
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6.0  OVERALL CONCLUSIONS AND PUBLIC HEALTH SIGNIFICANCE 
Currently, it is estimated that more than 1 of every 3 Americans has some type of prevalent 
CVD, and that prevalence is even greater in Blacks compared to Whites1. In the current study, 
we characterized the epidemiology and genetics of subclinical CVD in generally healthy, African 
ancestry families from the island of Tobago. Patterns of age- and sex-related differences in these 
measures were similar to previous reports in African ancestry populations, although measures of 
blood pressure and arterial stiffness may be more elevated in these families compared to African 
Americans. Carotid ultrasound measures were mainly associated with age, sex, body size and 
blood pressure. Measures of blood pressure and arterial stiffness were mainly determined by age, 
sex, body size and heart rate. Only pulse pressure was significantly related to menopausal status, 
and only pulse-wave velocity was associated with diabetes. These traditional CVD risk factors, 
along with smoking and lipid levels, were less predictive of subclinical CVD in this population 
than in previous reports. However, our sample was recruited from a very unique and 
geographically isolated island population, was relatively young, and characterized by different 
environmental risk factor profiles than Westernized societies. Thus, traditional CVD risk factors 
may be less strongly related to subclinical measures of CVD in our African ancestry families. 
Nonetheless, modifiable risk factors of subclinical CVD traits, such as excess body weight and 
blood pressure, were identified and should be a focus of efforts to improve CVD risk in the 
Tobago population.  
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We have also shown that there is a significant contribution of genetics to measures of 
subclinical CVD in these African ancestry families. Overall, measures of carotid ultrasound have 
a high proportion of variance due to genetics, compared to measures of blood pressure and 
arterial stiffness, which were less heritable. We conducted genome-wide univariate linkage 
analysis and identified genomic regions that may contribute to subclinical CVD measures, with 
the strongest linkage signal being on the q23 arm of chromosome 11 for adventitial diameter and 
lumen diameter. There was also a region identified on chromosome 14 q22-q24 with significant 
bivariate linkage for adventitial diameter and osteoporosis-related traits, as well as, univariate 
linkage to AD and LD. There are many potential candidate genes under these peaks including 
strong CVD-associated genes like the APOA1/C3/A4/A5 gene cluster, IL18 and ESR2. Further 
research will need to be done to refine these linkage peaks and identify the loci with univariate 
and/or pleiotropic effects on subclinical CVD and osteoporosis. 
These findings are important because they describe CVD traits in a unique population of 
African ancestry individuals with very low admixture6, which is unique compared to the United 
States and many Western European studies in Blacks. Also, the lifestyle factors for these 
individuals vary from most studies, which impacts the potential generalizability of our findings. 
While we did see a strong impact of some environmental factors, genetics determined a very 
large portion of the variance in subclinical CVD measures in these families.  
 We also found that body weight and blood pressure are the two strongest modifiable risk 
factors for subclinical CVD measures in these African ancestry families. These observations 
have significant public health importance as the rates of CVD continue to rise in Trinidad and 
Tobago316. We also determined that measures of subclinical CVD and osteoporosis are correlated 
both phenotypically and genetically. The genomic regions identified in these studies may provide 
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a starting place to refine the genetic determinants of CVD. Studying the genetic determinants of 
disease in ethnic minorities, such as these African ancestry families, can define ethnic 
differences in disease etiology, which will lead to ethnicity-specific therapeutic agents and risk 
prediction tools. Therefore, these data represent the critical first steps to ultimately understanding 
ethnic differences in disease progression and will hopefully aid in minimizing health disparities, 
which was, and continues to be, a major facet of the Healthy People 2010 and 2020 goals317. 
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APPENDIX 
SUPPLEMENTARY DATA 
Table 7.1 Univariate, Genome-Wide Linkage Results for Cardiovascular and BMD Traits 
Location Trait Max LOD* Chromosome cM (range)§ Genomic Mbp Cytogenetic 
Adventitial Diameter 4.71 14 54 (49-69) 52.9-73.4 q22.2-24.3 
Intima-media Thickness 2.36 13 114 (104-121) 99.6-107.1 q32.3-33.3 
Lumbar Spine BMD 2.53 1 104 (100-123) 64.0-90.3 p31.3-22.2 
Radial Cortical BMD 2.28 12 80 (72-85) 52.9-67.6 q13.13-15 
Tibial Cortical BMD 2.62 2 73 (56-84) 33.2-60.4 p22.3-16.1 
Tibial Cortical BMD 2.81 19 42 (40-46) 11.3-15.6 p13.2-13.12 
Radial Trabecular BMD 3.44 11 24 (15-50) 6.2-28.2 p15.4-14.1 
All regions with a peak LOD ≥ 2.2 in univariate analyses are shown 
*Analyses were adjusted for age, sex, weight, height, menopausal status, current smoking, 
alcohol intake and walking for exercise 
§ Range defined by the position of the peak LOD±1.0 where peak LOD<3.5 and defined as 
LOD±2.0 where peak LOD≥3.5 
BMD: bone mineral density 
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Figure 7.1 Univariate, Genome-Wide Linkage Results for Cardiovascular Traits 
LOD scores from univariate, genome-wide linkage analysis of cardiovascular traits are plotted 
by chromosome for each trait. Horizontal lines are drawn at LOD=2.0 and 3.3 to signify 
thresholds for suggestive and significant univariate linkage, respectively. 
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Figure 7.2 Univariate, Genome-Wide Linkage Results for BMD Related Traits 
LOD scores from univariate, genome-wide linkage analysis of BMD related traits are plotted by 
chromosome for each trait. Horizontal lines are drawn at LOD=2.0 and 3.3 to signify thresholds 
for suggestive and significant univariate linkage, respectively. BMD: bone mineral density  
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